

---

# CONTENTS

---

## PART **1**

---

### MOLECULAR BIOLOGY OF CANCER

#### **1**

*Molecular Methods in Oncology* . . . . .

**SECTION 1**    *Amplification Techniques*    3

PAUL M. LIZARDI

Improved Analysis of Mutations in Oncogenes and Tumor  
Suppressor Genes    3

Highly Parallelized Single-Nucleotide Polymorphism Assays Can Also Be  
Used for Somatic Genotyping    4

Increasing the Accuracy of Sequence Information Derived from Polymerase  
Chain Reaction Amplification    5

Multiplex Real-Time Polymerase Chain Reaction Amplification for Detection  
of Minimal Residual Disease or Viral Load    5

Mutation Detection Using *In Situ* Hybridization Methods Coupled with  
DNA Amplification    5

High-Throughput Methods for Measuring Gene  
Dosage Alterations    6

Whole Genome Amplification of Microdissected Tissue    6

Amplification of Genomic Representations for Analysis of Gene  
Gain/Loss    6

Tumor Classification Using Real-Time Polymerase Chain Reaction to  
Measure Messenger RNA Levels    6

|                                                                       |   |
|-----------------------------------------------------------------------|---|
| Biomarker Detection Using DNA-Amplified Immunoassays                  | 7 |
| Amplification-Based Approaches for DNA Methylation Analysis in Cancer | 7 |

## SECTION 2 *RNA Interference* 8

RICHARD A. MORGAN

Biochemistry and Function 8

RNA Interference in Mammals 10

Cancer Applications 11

## SECTION 3 *cDNA Arrays* 13

KEVIN M. BROWN

INGRID A. HEDENFALK

JEFFREY M. TRENT

DNA Microarrays and the Molecular Profiling of Human Cancers 13

Microarray Technology 13

Pediatric Acute Lymphoblastic Leukemia 15

Diffuse Large B-Cell Lymphoma 18

Breast Cancer 19

Microarrays, Tumor Aggressiveness, and Metastasis 21

Are DNA Microarrays Ready for Routine Clinical Management of Patients with Cancer? 22

Concluding Remarks 24

## SECTION 4 *Tissue Arrays* 26

MARISA DOLLED-FILHART

DAVID L. RIMM

Tissue Microarray Construction 26

Tissue Microarray Visualization 28

Tissue Microarray Analysis 29

Tissue Microarray Applications 32

## SECTION 5 *Cytogenetics* 34

MAZIN B. QUMSIYEH

YESIM YILMAZ

Chromosome Structure and Function 34

Cytogenetic Methods 36

Chromosome Abnormalities in Cancer 38

Data Mining in Cancer Cytogenetics 42

## SECTION 6 *Bioinformatics* 43

KENNETH H. BUETOW

"Flavors" of Bioinformatics 44

Biomedical Informatics 44

Electronic Information Provisioning 44

*In Silico* Biomedical Applications 46

The Future 50

**2*****Genomics and Proteomics* . . . . . 51**

KATHERINE R. CALVO  
 EMANUEL F. PETRICIOIN III  
 LANCE A. LIOTTA

- Understanding Cancer at the Molecular Level: An Evolving Frontier** 51  
**Genetic Mechanisms of Cancer Progression** 51  
**Postgenome Challenge for Molecular Medicine** 57  
**Tissue Microdissection Technology Brings Molecular Analysis to the Tissue Level** 58  
**Complementary DNA Microarrays As a Tool to Analyze Gene Expression Patterns in Human Cancer** 59  
**Beyond Functional Genomics to Cancer Proteomics** 63  
**Molecular Diagnostics and Individualized Cancer Therapy** 63  
**Serum Proteomics** 67

**3*****Molecular Targets in Oncology* . . . . . 73****SECTION 1 *Signal Transduction Systems* 73**

CHRISTOPHER L. CARPENTER  
 LEWIS C. CANTLEY

- Sensory Machinery: Ligands and Receptors** 73  
**Propagation of Signals to the Cell Interior** 76  
**Efficiency and Specificity: Formation of Multiprotein Signaling Complexes** 80  
**Regulation of Protein Levels: Transcription, Translation, and Proteolysis** 81

**SECTION 2 *Cell Cycle* 83**

STEVEN I. REED

- Cell-Cycle Engine** 83  
**Regulation of the Cell Cycle** 87  
**Cell Cycle and Cancer** 90  
**Cell Cycle As a Target for Therapy** 93  
**Conclusion** 94

**SECTION 3 *Apoptosis* 95**

SANDRA S. ZINKEL  
 STANLEY J. KORSMEYER

- Genetics of Cell Death** 95  
**Bcl-2 Family** 95  
**Critical Role of Apoptosis in Tissue Homeostasis** 98  
**Caspases** 99  
**Death Receptors** 99  
**Apoptosome** 99  
**Inhibitors of Apoptosis** 101  
**Role of Intracellular Organelles: Mitochondria and Endoplasmic Reticulum** 101  
**Cell Proliferation and Apoptosis** 101  
**Possibilities for Therapeutic Intervention** 102  
**Conclusion** 102

## SECTION 4 *Telomerase* 105

KWOK-KIN WONG  
RONALD A. DEPINHO

Telomeres 105

Telomerase Structure, Regulation, and Function 106

Crisis, Telomerase Reactivation, and Alternative Lengthening of Telomeres 106

Telomere Maintenance and Cancer 107

Aging and Cancer 107

Telomere Dynamics, Inflammatory Diseases, and Cancer 108

Telomere Status as a Biomarker for Cancer 109

Telomerase and Telomere Maintenance As Therapeutic Targets 109

Rational Clinical Trial Designs of Telomere- and Telomerase-  
Based Therapeutics 111

## 4

### *Invasion and Metastases* ..... 113

WILLIAM G. STETLER-STEVENSON

Tumor Progression and Genetic Instability 113

Origins of Metastatic Tumor Cells 114

Microarray Analysis of Tumor Progression and Metastasis 115

Tumorigenesis and Metastasis Are Under Separate Genetic Control: Tumor Suppressor Genes 116

Metastatic Cascade 117

Tumor Microenvironment: Determinant of Metastatic Potential and Site of Metastasis 118

Tumor Cell Motility 119

Tumor Invasion of the Basement Membrane 119

Initiation of Cell Migration 119

Cell–Cell Adhesion: Metastasis Suppressor 120

Cell Matrix Interactions and Tumor Cell Migration 121

Role of CD44 in Tumor Invasion and Metastasis 121

Role of Integrins in Tumor Progression 122

Cell Migration 124

Proteases in Tumor Cell Invasion 125

Conclusion 126

## 5

### *Angiogenesis* ..... 129

ISAIAH J. FIDLER  
ROBERT R. LANGLEY  
ROBERT S. KERBEL  
LEE M. ELLIS

Neoplastic Angiogenesis 129

Phenotypic Diversity of Organ-Specific Endothelial Cells 131

Tumor Vasculature 132

Host-Mediated Angiogenesis 132

Overview of Antiangiogenic and Antivascular Therapies 133

Antivascular Therapy for Bone Metastasis 134

Clinical Studies of Imatinib 135

Discrepancy between Results of Preclinical and Clinical Trials 135

|                                                                         |     |
|-------------------------------------------------------------------------|-----|
| Basic Principles for Design of Clinical Trials of Antiangiogenic Agents | 135 |
| Conclusion                                                              | 136 |

|                                                                  |       |            |
|------------------------------------------------------------------|-------|------------|
| <b>6</b>                                                         |       |            |
| <i>Cancer Immunology</i>                                         | ..... | <b>139</b> |
| NICHOLAS P. RESTIFO                                              |       |            |
| JOHN R. WUNDERLICH                                               |       |            |
| Antitumor T Cells                                                | 140   |            |
| Biologic Sources of Tumor-Associated Antigens                    | 140   |            |
| Presentation of Tumor Antigens to T Cells                        | 141   |            |
| Role of Antigen-Presenting Cells in Activating Antitumor T Cells | 146   |            |
| T-Cell Recognition of Tumor Antigens                             | 148   |            |
| Maturation of Antitumor T Cells                                  | 149   |            |
| Activation of Mature Antitumor T Cells                           | 150   |            |
| Activation States of Antitumor T Cells                           | 154   |            |
| Functions of Mature Antitumor T Cells                            | 155   |            |
| Conclusion                                                       | 157   |            |

## **PART 2**

### **PRINCIPLES OF ONCOLOGY**

|                                    |                                                                     |            |
|------------------------------------|---------------------------------------------------------------------|------------|
| <b>7</b>                           |                                                                     |            |
| <i>Etiology of Cancer: Viruses</i> | .....                                                               | <b>165</b> |
| <b>SECTION 1</b>                   | <b>RNA Viruses</b>                                                  | <b>165</b> |
|                                    | GARY L. BUCHSCHACHER, JR.                                           |            |
|                                    | FLOSSIE WONG-STAAAL                                                 |            |
|                                    | Retroviruses: Background, Replication Cycle, and Molecular Genetics | 165        |
|                                    | Mechanisms of Retroviral Oncogenesis                                | 166        |
|                                    | Human T-Lymphotropic Virus Type 1                                   | 168        |
|                                    | Human T-Lymphotropic Virus Type 2                                   | 169        |
|                                    | Human Immunodeficiency Virus                                        | 169        |
|                                    | Hepatitis C Virus                                                   | 171        |
| <b>SECTION 2</b>                   | <b>DNA Viruses</b>                                                  | <b>173</b> |
|                                    | PETER M. HOWLEY                                                     |            |
|                                    | DON GANEM                                                           |            |
|                                    | ELLIOT KIEFF                                                        |            |
|                                    | Hepadnaviruses and Hepatocellular Carcinoma                         | 174        |
|                                    | Papillomaviruses and Human Cancer                                   | 175        |
|                                    | Epstein-Barr Virus                                                  | 180        |
|                                    | Kaposi's Sarcoma-Associated Herpesvirus                             | 181        |
|                                    | Simian Vacuolating Virus 40 and the Human Polyomaviruses            | 183        |

## 8

*Etiology of Cancer: Chemical Factors* ..... 185

STUART H. YUSPA

PETER G. SHIELDS

Nature of Chemical Carcinogens: Chemistry and Metabolism 185

Animal Model Systems and Chemical Carcinogenesis 186

DNA Repair Protects the Host from Chemical Carcinogens 187

Genetic Susceptibility to Chemical Carcinogenesis 187

Determination of Chemical Carcinogens for Humans and Population-  
Based Risk Assessment 187

Chemical Carcinogenesis and Cancer Risk 187

Tumor Suppressor Genes in Human Cancer 189

Tobacco Smoking and Cancer Risk 190

## 9

*Etiology of Cancer: Tobacco Use* ..... 193

GRAHAM A. COLDITZ

LAURIE B. FISHER

Effects of Tobacco Use and Cessation on Cancer Risk 193

Effect of Tobacco Use on Cardiovascular Disease 196

Cigars, Pipes, and Smokeless Tobacco 196

Secondhand Tobacco Smoke 197

National Trends in Smoking Prevalence 197

Disparities in Active Tobacco Use and Cessation 197

Cigarette Product Modification—Harm Reduction 198

Tobacco and Nicotine Addiction 198

Role of the Clinician 198

Strategies for Tobacco Control 198

Conclusion 198

## 10

*Etiology of Cancer: Physical Factors* ..... 201

ROBERT L. ULLRICH

Interactions of Radiation with Cells and Tissues 202

Ultraviolet Light 211

Asbestos 213

## 11

*Epidemiology of Cancer* ..... 217SECTION 1 *Epidemiologic Methods* 217

XIAOMEI MA

MARGARET A. TUCKER

Descriptive Studies 218

Analytic Studies 219  
Interpretation of Epidemiologic Findings 222  
Special Topic: Molecular and Genetic Epidemiology 223

**SECTION 2 Cancer Statistics 226**  
AHMEDIN JEMAL  
ELIZABETH M. WARD  
MICHAEL J. THUN  
Measures of the Cancer Burden 226  
Data Sources and Age Standardization 230  
Temporal Trends 231  
Demographic and Geographic Patterns 234  
Issues in the Interpretation and Understanding of  
Temporal Trends 238  
Conclusion 240

**12**  
***Principles of Surgical Oncology . . . . . 243***

**SECTION 1 General Issues 243**  
STEVEN A. ROSENBERG  
Historical Perspective 243  
Anesthesia for Oncologic Surgery 244  
Determination of Operative Risk 246  
Roles for Surgery 249  
Surgical Oncologist 251

**SECTION 2 Laparoscopic Surgery 253**  
ALBERT S. KO  
ALAN T. LEFOR  
Physiology of Laparoscopy 253  
Port-Site Metastases 255  
Laparoscopy in the Diagnosis of Malignancy 257  
Laparoscopy in the Staging of Malignancy 258  
Laparoscopy in the Treatment of Malignancy 263  
Laparoscopy in the Palliation of Malignancy 265  
Conclusion 265

**13**  
***Principles of Radiation Oncology . . . . . 267***

PHILIP P. CONNELL  
MARY K. MARTEL  
SAMUEL HELLMAN  
Biologic Aspects of Radiation Oncology 267  
Physical Aspects of Radiation Oncology 276  
Clinical Aspects of Radiation Oncology 285

# 14

## *Principles of Medical Oncology. . . . . 295*

EDWARD CHU

VINCENT T. DEVITA, JR.

**Historical Perspective** 295**Clinical Application of Chemotherapy** 296**Clinical End Points in Evaluating Response to Chemotherapy** 297**Cancer Cell Kinetics and Response to Chemotherapy** 298**Principles Governing the Use of Chemotherapy** 298**Concept of Dose Intensity** 300**Apoptosis, Cell-Cycle Control, and Resistance to Chemotherapy** 301

# 15

## *Pharmacology of Cancer Chemotherapy. . . . . 307*

### *SECTION 1 Drug Development 307*

EDWARD CHU

**Drug Discovery** 307**Combinatorial Chemistry** 309**Drug Screening** 311**Molecularly Targeted Screening** 312**Preclinical Pharmacology** 313**Formulation Studies** 314**Preclinical Toxicology** 315**Clinical Development** 315**Conclusion** 316

### *SECTION 2 Pharmacokinetics 317*

CHRIS H. TAKIMOTO

**Introduction** 317**Pharmacokinetic Concepts** 319**Pharmacodynamic Concepts** 323**Special Topics in Pharmacokinetics and Pharmacodynamics** 324**Pharmacokinetics and Pharmacodynamics in Oncology Drug Development** 325**Conclusion** 326

### *SECTION 3 Pharmacogenomics 327*

HOWARD L. MCLEOD

BOON-CHER GOH

**Pharmacogenomics of Chemotherapy Drug Toxicity** 327**Pharmacogenomics of Tumor Response** 330**Conclusion** 331

### *SECTION 4 Alkylating Agents 332*

O. MICHAEL COLVIN

HENRY S. FRIEDMAN

**History of the Alkylating Agents** 332

|                                                   |     |
|---------------------------------------------------|-----|
| Chemistry and Cytotoxicity of Alkylating Agents   | 332 |
| Classes of Alkylating Agents and Their Properties | 332 |
| Mechanisms of Toxicity and Drug Resistance        | 338 |
| Common Toxicities of Alkylating Agents            | 340 |

## SECTION 5 *Cisplatin and Its Analogues* 344

STEVEN W. JOHNSON

PETER J. O'DWYER

History 344

Platinum Chemistry 345

Novel Platinum Complexes 345

Mechanism of Action 347

Mechanisms of Resistance 349

Clinical Pharmacology 352

Formulation and Administration 354

Toxicity 354

## SECTION 6 *Antimetabolites* 358

SHIVAANI KUMMAR

VANITA NORONHA

EDWARD CHU

Methotrexate 358

New Antifolates 361

## SECTION 7 *Topoisomerase Interactive Agents* 375

CHRIS H. TAKIMOTO

Mammalian Topoisomerases 375

Mechanism of Action of Topoisomerase Interactive Agents 377

Camptothecins 377

Epipodophyllotoxins 381

Anthracyclines and Related Compounds 384

Other Topoisomerase Interactive Agents 388

Secondary Malignancies and Topoisomerase Targeting Therapies 389

## SECTION 8 *Antimicrotubule Agents* 390

ERIC K. ROWINSKY

ANTHONY W. TOLCHER

Microtubules 390

Vinca Alkaloids 392

Taxanes 398

Estramustine Phosphate 407

Novel Compounds Targeting Microtubules 410

Novel Compounds Targeting Mitotic Motor Proteins 411

## SECTION 9 *Miscellaneous Chemotherapeutic Agents* 416

MEHMET SITKI COPUR

MICHAL G. ROSE

EDWARD CHU

L-Asparaginase 416

|                   |     |
|-------------------|-----|
| Bleomycin         | 417 |
| Imatinib Mesylate | 417 |
| Gefitinib         | 418 |
| Bortezomib        | 420 |

# 16

## *Pharmacology of Cancer Biotherapeutics. . . . . 423*

### *SECTION 1 Interferons 423*

|                                                |     |
|------------------------------------------------|-----|
| VERNON K. SONDAK                               |     |
| BRUCE G. REDMAN                                |     |
| Interferon Induction                           | 423 |
| Biologic Effects of Interferons                | 424 |
| Clinical Toxicity of Interferon Administration | 426 |
| Potential Drug Interactions                    | 427 |
| Oncologic Applications of Interferons          | 427 |
| Conclusion                                     | 429 |

### *SECTION 2 Interleukin-2 431*

|                                                              |     |
|--------------------------------------------------------------|-----|
| JAMES W. MIER                                                |     |
| MICHAEL B. ATKINS                                            |     |
| Isolation, Characterization, and Cloning of Interleukin-2    | 431 |
| Interleukin-2 Receptor                                       | 431 |
| Interleukin-2-Activated Signaling Pathways                   | 431 |
| <i>In Vitro</i> Effects of Interleukin-2                     | 432 |
| Preclinical Studies with Interleukin-2 in Tumor-Bearing Mice | 432 |
| Clinical Applications of Interleukin-2                       | 432 |
| Conclusion                                                   | 437 |

### *SECTION 3 Histone Deacetylase Inhibitors: New Targeted Anticancer Drugs 439*

|                                                                                 |     |
|---------------------------------------------------------------------------------|-----|
| PAUL A. MARKS                                                                   |     |
| VICTORIA M. RICHON                                                              |     |
| THOMAS A. MILLER                                                                |     |
| WM. KEVIN KELLY                                                                 |     |
| Chromatin Structure                                                             | 439 |
| Histone Deacetylases and Histone Acetyl Transferases                            | 439 |
| Histone Acetyltransferases and Histone Deacetylase Inhibitors and Human Cancers | 439 |
| Histone Deacetylase Inhibitors                                                  | 441 |
| Activity of Histone Deacetylase Inhibitors                                      | 441 |
| Clinical Trials with Histone Deacetylase Inhibitors                             | 443 |
| Conclusion and Perspectives                                                     | 444 |

### *SECTION 4 Monoclonal Antibodies 445*

|                          |     |
|--------------------------|-----|
| JONATHAN D. CHENG        |     |
| GREGORY PAUL ADAMS       |     |
| MATTHEW K. ROBINSON      |     |
| LOUIS M. WEINER          |     |
| Immunoglobulin Structure | 446 |

|                                                                |     |
|----------------------------------------------------------------|-----|
| Factors Regulating Antibody-Based Tumor Targeting              | 447 |
| Unconjugated Antibodies                                        | 448 |
| Immunoconjugates                                               | 451 |
| Pretargeted Antibody Conjugates                                | 453 |
| Unconjugated Antibodies with Clinical Activity in Solid Tumors | 453 |
| Conclusion                                                     | 454 |

# 17

|                                               |     |
|-----------------------------------------------|-----|
| <i>Pharmacology of Endocrine Manipulation</i> | 457 |
|-----------------------------------------------|-----|

MATTHEW P. GOETZ  
CHARLES ERLICHMAN  
CHARLES L. LOPRINZI

|                                            |     |
|--------------------------------------------|-----|
| Selective Estrogen Receptor Modulators     | 457 |
| Medroxyprogesterone and Megestrol          | 461 |
| Aromatase Inhibitors                       | 462 |
| Gonadotropin-Releasing Hormone Analogues   | 464 |
| Antiandrogens                              | 464 |
| Fluoxymesterone                            | 465 |
| Diethylstilbestrol and Estradiol (Estrace) | 465 |
| Octreotide                                 | 466 |

# 18

|                                               |     |
|-----------------------------------------------|-----|
| <i>Design and Analysis of Clinical Trials</i> | 471 |
|-----------------------------------------------|-----|

RICHARD M. SIMON

|                                       |     |
|---------------------------------------|-----|
| Phase I Clinical Trials               | 471 |
| Phase II Clinical Trials              | 473 |
| Design of Phase III Clinical Trials   | 478 |
| Analysis of Phase III Clinical Trials | 483 |

## PART 3

## PRACTICE OF ONCOLOGY

# 19

|                                                              |     |
|--------------------------------------------------------------|-----|
| <i>Cancer Prevention: Preventing Tobacco-Related Cancers</i> | 493 |
|--------------------------------------------------------------|-----|

HOWARD K. KOH  
ALAN C. GELLER

|                                             |     |
|---------------------------------------------|-----|
| Tobacco and Nicotine Addiction              | 493 |
| Health Effects                              | 493 |
| Smoking Rates and Trends                    | 494 |
| Adults                                      | 494 |
| Children, Adolescents, and College Students | 495 |

|                                                                                     |     |
|-------------------------------------------------------------------------------------|-----|
| Cigarette Product Modification                                                      | 495 |
| Spit Tobacco                                                                        | 496 |
| Cigars                                                                              | 496 |
| Environmental Tobacco Smoke                                                         | 496 |
| Tobacco Industry Advertising Strategies                                             | 497 |
| Strategies for Tobacco Control                                                      | 498 |
| Individual Approaches                                                               | 498 |
| Clinician's Role                                                                    | 498 |
| Nicotine Replacement Therapy                                                        | 499 |
| Special Populations                                                                 | 500 |
| National Action Plan for Tobacco Cessation                                          | 500 |
| Tobacco Restrictions at the Policy Level                                            | 500 |
| Tobacco Taxes that Fund Dedicated, Comprehensive Statewide Tobacco Control Programs | 500 |
| Mass Media and Counter-Advertising                                                  | 501 |
| Tobacco Litigation, Tobacco Settlement, and International Treaties                  | 502 |
| Proposed U.S. Food and Drug Administration Regulations                              | 502 |
| Conclusion                                                                          | 503 |

## 20

### *Cancer Prevention: Diet and Chemopreventive Agents . . . . . 507*

#### *SECTION 1 Dietary Fat 507*

WALTER C. WILLETT

|                         |     |
|-------------------------|-----|
| Fat and Breast Cancer   | 508 |
| Fat and Colon Cancer    | 509 |
| Fat and Prostate Cancer | 510 |
| Fat and Other Cancers   | 511 |
| Conclusion              | 511 |

#### *SECTION 2 Dietary Fiber 514*

KARIN B. MICHELS

|                                           |     |
|-------------------------------------------|-----|
| Diet and Cancer Etiology                  | 514 |
| Properties of Dietary Fiber               | 514 |
| Observational Studies and Clinical Trials | 514 |
| Types of Dietary Fiber                    | 515 |
| Calculation of Fiber Intake               | 515 |
| Dietary Fiber and Colorectal Cancer       | 515 |
| Fiber Intake and Colorectal Adenomas      | 516 |
| Fiber Intake and Breast Cancer            | 516 |
| Dietary Fiber and Stomach Cancer          | 516 |
| Timing of Diet                            | 517 |
| Conclusion                                | 517 |

#### *SECTION 3 Fruit and Vegetable Consumption 518*

KARIN B. MICHELS

|                                                       |     |
|-------------------------------------------------------|-----|
| Fruits and Vegetables                                 | 518 |
| Diet Assessment Instruments                           | 518 |
| Confounding                                           | 518 |
| Fruit and Vegetable Consumption and Colorectal Cancer | 518 |

|                                                              |     |
|--------------------------------------------------------------|-----|
| Fruit and Vegetable Consumption and Stomach Cancer           | 518 |
| Fruit and Vegetable Consumption and Breast Cancer            | 519 |
| Fruit and Vegetable Consumption and Lung Cancer              | 519 |
| Micronutrient Components of Fruits and Vegetables and Cancer | 519 |
| Conclusion                                                   | 520 |

## **SECTION 4**    *Retinoids, Carotenoids, and Micronutrients*    521

|                                                                              |     |
|------------------------------------------------------------------------------|-----|
| SUSAN T. MAYNE                                                               |     |
| SCOTT M. LIPPMAN                                                             |     |
| Historical Perspective                                                       | 521 |
| Retinoid Biology and Pharmacology                                            | 522 |
| Carotenoid Biology and Actions                                               | 522 |
| Clinical Trials                                                              | 523 |
| Translational and Intermediate End Point Studies in Retinoid Chemoprevention | 532 |
| Other Retinoids and Carotenoids                                              | 533 |
| Conclusion                                                                   | 533 |

## **SECTION 5**    *Dietary Carcinogens*    536

|                                             |     |
|---------------------------------------------|-----|
| PETER GREENWALD                             |     |
| Naturally Occurring Dietary Carcinogens     | 536 |
| Products of Food Preparation and Processing | 538 |
| Synthetic Carcinogens in the Diet           | 540 |
| Future Research Needs                       | 540 |

## **SECTION 6**    *Cyclooxygenase Inhibitors*    541

|                                                                  |     |
|------------------------------------------------------------------|-----|
| MICHAEL J. THUN                                                  |     |
| S. JANE HENLEY                                                   |     |
| Pharmacology of Nonsteroidal Antiinflammatory Drugs              | 541 |
| Toxicity of Nonsteroidal Antiinflammatory Drugs                  | 542 |
| History of the Inflammation Hypothesis                           | 542 |
| Nonsteroidal Antiinflammatory Drugs in Relation to Other Cancers | 543 |
| Mechanisms of Cancer Inhibition                                  | 544 |
| Molecular Target(s)                                              | 546 |
| Ongoing Randomized Clinical Trials                               | 546 |
| Implications for Research and Clinical Practice                  | 546 |
| Conclusion                                                       | 548 |

## **SECTION 7**    *Physical Activity and Body Weight*    549

|                     |     |
|---------------------|-----|
| GRAHAM A. COLDITZ   |     |
| KATHLEEN YAUS WOLIN |     |
| Physical Activity   | 549 |
| Obesity             | 552 |
| Conclusion          | 553 |

# **21**

|                                                                          |            |
|--------------------------------------------------------------------------|------------|
| <i>Cancer Prevention: Role of Surgery in Cancer Prevention</i> . . . . . | <b>555</b> |
|--------------------------------------------------------------------------|------------|

RICHARD M. SHERRY

|                                                                              |     |
|------------------------------------------------------------------------------|-----|
| Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma | 555 |
|------------------------------------------------------------------------------|-----|

|                                           |     |
|-------------------------------------------|-----|
| Barrett's Esophagus and Esophageal Cancer | 556 |
| Hereditary Diffuse Gastric Cancer         | 558 |
| Colorectal Cancer                         | 558 |
| Breast Cancer                             | 561 |
| Ovarian Cancer                            | 563 |
| Testicular Cancer and Cryptorchidism      | 564 |

## 22

|                                   |            |
|-----------------------------------|------------|
| <i>Cancer Screening</i> . . . . . | <b>567</b> |
|-----------------------------------|------------|

|                                |     |
|--------------------------------|-----|
| BARBARA K. RIMER               |     |
| JOELLEN M. SCHILDKRAUT         |     |
| ROBERT A. HIATT                |     |
| What Is Cancer Screening?      | 567 |
| Evaluation of a Screening Test | 568 |
| Breast Cancer Screening        | 569 |
| Cervical Cancer Screening      | 572 |
| Colorectal Cancer Screening    | 573 |
| Skin Cancer Screening          | 574 |
| Prostate Cancer Screening      | 574 |
| Lung Cancer Screening          | 576 |
| Adherence to Cancer Screening  | 577 |
| Future of Screening            | 577 |

## 23

|                                                 |            |
|-------------------------------------------------|------------|
| <i>Advanced Molecular Diagnostics</i> . . . . . | <b>581</b> |
|-------------------------------------------------|------------|

|                                                           |     |
|-----------------------------------------------------------|-----|
| JOSÉ C. COSTA                                             |     |
| PAUL M. LIZARDI                                           |     |
| Present Impact of Novel Technologies on Clinical Practice | 582 |
| Charting the Future                                       | 584 |
| Conclusion                                                | 586 |

## 24

|                                           |            |
|-------------------------------------------|------------|
| <i>Advanced Imaging Methods</i> . . . . . | <b>589</b> |
|-------------------------------------------|------------|

|                                                          |            |
|----------------------------------------------------------|------------|
| <b>SECTION 1</b> <i>Functional and Metabolic Imaging</i> | <b>589</b> |
|----------------------------------------------------------|------------|

|                                 |     |
|---------------------------------|-----|
| HEDVIG HRICAK                   |     |
| OGUZ AKIN                       |     |
| MICHELLE S. BRADBURY            |     |
| LAURA LIBERMAN                  |     |
| LAWRENCE H. SCHWARTZ            |     |
| STEVEN M. LARSON                |     |
| Imaging Modalities              | 589 |
| Therapeutic Response Assessment | 594 |
| Brain and Head/Neck Cancers     | 595 |
| Lung Cancer                     | 597 |
| Lymphoma                        | 600 |
| Breast Cancer                   | 601 |
| Hepatobiliary Cancer            | 604 |
| Colorectal Cancer               | 605 |

|                               |     |
|-------------------------------|-----|
| Gynecologic Cancer            | 607 |
| Endometrial Cancer            | 607 |
| Cervical Cancer               | 608 |
| Ovarian Cancer                | 609 |
| Prostate Cancer               | 610 |
| Molecular Imaging in Oncology | 611 |

## SECTION 2 *Interventional Radiology* 617

|                                          |     |
|------------------------------------------|-----|
| ANNE M. COVEY                            |     |
| KAREN T. BROWN                           |     |
| Percutaneous Biopsy                      | 617 |
| Central Venous Access                    | 619 |
| Gastrointestinal Procedures              | 619 |
| Genitourinary Procedures                 | 620 |
| Biliary Procedures                       | 623 |
| Chest Interventions                      | 626 |
| Inferior Vena Cava Filters               | 629 |
| Ascites                                  | 630 |
| Abscess Drainage                         | 631 |
| Embolotherapy for Hepatic Neoplasms      | 631 |
| Tumor Ablation                           | 632 |
| Emerging Therapies and Future Directions | 634 |

# 25

|                                              |            |
|----------------------------------------------|------------|
| <i>Cancer Diagnosis: Endoscopy</i> . . . . . | <b>637</b> |
|----------------------------------------------|------------|

## SECTION 1 *Gastrointestinal Endoscopy* 637

|                                                |     |
|------------------------------------------------|-----|
| IRVING WAXMAN                                  |     |
| Upper Endoscopy                                | 637 |
| Colonoscopy                                    | 640 |
| Endoscopic Ultrasonography                     | 641 |
| Small Bowel Endoscopy and Capsule Endoscopy    | 641 |
| Endoscopic Retrograde Cholangiopancreatography | 642 |

## SECTION 2 *Respiratory Tract* 643

|                                                      |     |
|------------------------------------------------------|-----|
| DAO M. NGUYEN                                        |     |
| RONALD M. SUMMERS                                    |     |
| STEVEN E. FINKELSTEIN                                |     |
| Bronchoscopy                                         | 643 |
| Virtual Bronchoscopy                                 | 645 |
| Cervical Mediastinoscopy and Anterior Mediastinotomy | 647 |
| Video-Assisted Thoracoscopy                          | 648 |

# 26

|                                              |            |
|----------------------------------------------|------------|
| <i>Cancer of the Head and Neck</i> . . . . . | <b>653</b> |
|----------------------------------------------|------------|

## SECTION 1 *Molecular Biology of Head and Neck Tumors* 653

|                        |     |
|------------------------|-----|
| DAVID SIDRANSKY        |     |
| Genetic Susceptibility | 653 |

Cytogenetic Alterations 653  
Protooncogenes 654  
Suppressive Growth Regulation 655  
Tumor Suppressor Genes 655  
Field Cancerization 657  
Molecular Epidemiology 658  
Human Papillomavirus 658  
Diagnostics 658

SECTION 2 Treatment of Head and Neck Cancers 662

WILLIAM M. MENDENHALL  
CHARLES E. RIGGS, JR.  
NICHOLAS J. CASSISI  
Epidemiology of Head and Neck Cancer 662  
Anatomy 662  
Pathology 662  
Natural History and Patterns of Spread of Squamous  
Cell Carcinoma 663  
Diagnostic Evaluation 665  
Staging 665  
General Principles for Selection of Treatment 665  
Management 666

SECTION 3 Rehabilitation after Treatment for Head and Neck Cancer 732

MICHAEL A. CRARY  
GISELLE D. CARNABY (MANN)  
General Functional Consequences of Treatment for Head and  
Neck Cancer 732  
Tracheostomy Issues 734  
Radiation Therapy Impact on Speech, Voice, and Swallowing  
Functions 735  
Evaluation of Speech, Voice, and Swallowing after Head and Neck  
Cancer Treatment 736  
Rehabilitation of Posttreatment Functional Limitations 738  
Conclusion 742

27 Cancer of the Lung. . . . . 745

SECTION 1 Molecular Biology of Lung Cancer 745

YOSHITAKA SEKIDO  
KWUN M. FONG  
JOHN D. MINNA  
Genetic and Epigenetic Alterations in Lung Cancers 745  
Protooncogenes and Growth Stimulation 746  
Tumor Suppressor Genes and Growth Suppression 748  
Other Biologic Abnormalities for Lung Cancer Development 749  
Molecular Tools in the Lung Cancer Clinic 751

|                  |                                                                   |            |
|------------------|-------------------------------------------------------------------|------------|
| <b>SECTION 2</b> | <b><i>Non–Small Cell Lung Cancer</i></b>                          | <b>753</b> |
|                  | DAVID S. SCHRUMP                                                  |            |
|                  | NASSER K. ALTORKI                                                 |            |
|                  | CLAUDIA L. HENSCHKE                                               |            |
|                  | DARRYL CARTER                                                     |            |
|                  | ANDREW T. TURRISI                                                 |            |
|                  | MARTIN E. GUTIERREZ                                               |            |
|                  | Incidence                                                         | 753        |
|                  | Etiology                                                          | 753        |
|                  | Pathology                                                         | 757        |
|                  | Modes of Metastasis                                               | 761        |
|                  | Clinical Manifestations                                           | 762        |
|                  | Staging and Diagnosis                                             | 763        |
|                  | Methods to Establish Tissue Diagnosis                             | 766        |
|                  | Lung Cancer Screening                                             | 768        |
|                  | Chemoprevention                                                   | 770        |
|                  | Overview of Invasive Lung Cancer Management: Treatment Modalities | 770        |
|                  | Specifics of Lung Cancer Management                               | 777        |
| <br>             |                                                                   |            |
| <b>SECTION 3</b> | <b><i>Small Cell Lung Cancer</i></b>                              | <b>810</b> |
|                  | JOHN R. MURREN                                                    |            |
|                  | ANDREW T. TURRISI                                                 |            |
|                  | HARVEY I. PASS                                                    |            |
|                  | Epidemiology and Etiology                                         | 810        |
|                  | Pathology                                                         | 810        |
|                  | Clinical Presentation                                             | 811        |
|                  | Staging Evaluation and Prognostic Factors                         | 812        |
|                  | Treatment                                                         | 815        |
|                  | Combination Chemotherapy                                          | 816        |
|                  | Duration of Chemotherapy                                          | 818        |
|                  | Approach to Patients with Limited Disease                         | 819        |
|                  | Role of Radiotherapy in Limited Disease                           | 820        |
|                  | Role of Surgery in Limited Disease                                | 823        |
|                  | Approach to Patients with Extensive Disease                       | 826        |
|                  | Strategies to Optimize Chemotherapy Response                      | 827        |
|                  | Hematopoietic Growth Factors                                      | 830        |
|                  | Management of Small Cell Lung Cancer in the Elderly and Infirm    | 832        |
|                  | Biologic Response Modifiers and Other Treatments                  | 833        |
|                  | Treatment at Relapse                                              | 834        |
|                  | Treatment Outcome and Long-Term Survival                          | 835        |
|                  | Extrapulmonary Small Cell Carcinoma                               | 836        |

|           |                                            |            |
|-----------|--------------------------------------------|------------|
| <b>28</b> | <b><i>Neoplasms of the Mediastinum</i></b> | <b>845</b> |
|           | ROBERT B. CAMERON                          |            |
|           | PATRICK J. LOEHRER, SR.                    |            |
|           | CHARLES R. THOMAS, JR.                     |            |
|           | Anatomy                                    | 845        |
|           | Incidence and Pathology                    | 845        |
|           | Diagnostic Considerations                  | 846        |

|                              |     |
|------------------------------|-----|
| Thymic Neoplasms             | 848 |
| Germ Cell Tumors             | 852 |
| Mesenchymal Tumors           | 855 |
| Neurogenic Tumors            | 855 |
| Primary Cardiac Malignancies | 858 |

## 29

|                                                        |     |
|--------------------------------------------------------|-----|
| <i>Cancers of the Gastrointestinal Tract</i> . . . . . | 861 |
|--------------------------------------------------------|-----|

### SECTION 1 *Cancer of the Esophagus* 861

|                                               |     |
|-----------------------------------------------|-----|
| MITCHELL C. POSNER                            |     |
| ARLENE A. FORASTIERE                          |     |
| BRUCE D. MINSKY                               |     |
| Epidemiology                                  | 861 |
| Etiologic Factors and Predisposing Conditions | 862 |
| Applied Anatomy and Histology                 | 865 |
| Molecular Biology                             | 867 |
| Natural History and Patterns of Failure       | 869 |
| Clinical Presentation                         | 869 |
| Diagnostic Studies and Pretreatment Staging   | 870 |
| Pathologic Staging                            | 871 |
| Treatment                                     | 872 |
| Stage-Directed Treatment Recommendations      | 901 |

### SECTION 2 *Cancer of the Stomach* 909

|                                                   |     |
|---------------------------------------------------|-----|
| PETER W. T. PISTERS                               |     |
| DAVID P. KELSEN                                   |     |
| STEVEN M. POWELL                                  |     |
| JOEL E. TEPPER                                    |     |
| Epidemiology and Etiology                         | 909 |
| Molecular Biology                                 | 912 |
| Pathology and Tumor Biology                       | 914 |
| Clinical Presentation and Pretreatment Evaluation | 915 |
| Staging, Classification, and Prognosis            | 917 |
| Treatment of Localized Disease                    | 921 |
| Treatment of Advanced Disease (Stage IV)          | 934 |

### SECTION 3 *Cancer of the Pancreas* 945

|                                |     |
|--------------------------------|-----|
| CHARLES J. YEO                 |     |
| THERESA PLUTH YEO              |     |
| RALPH H. HRUBAN                |     |
| SCOTT E. KERN                  |     |
| CHRISTINE A. IACOBUZIO-DONOHUE |     |
| ANIRBAN MAITRA                 |     |
| MICHAEL GOGGINS                |     |
| MARCIA I. CANTO                |     |
| WELLS MESSERSMITH              |     |
| ROSS A. ABRAMS                 |     |
| DANIEL A. LAHERU               |     |
| MANUEL HIDALGO                 |     |
| ELIZABETH M. JAFFEE            |     |
| Epidemiology and Risk Factors  | 945 |

|                                               |     |
|-----------------------------------------------|-----|
| Pathology                                     | 947 |
| Molecular Genetics                            | 950 |
| Gene Expression Profiling and Beyond          | 952 |
| Screening and Early Detection                 | 953 |
| Clinicopathologic Staging                     | 955 |
| Clinical Presentation and Evaluation          | 957 |
| Treatment of Potentially Resectable Disease   | 960 |
| Treatment of Locally Advanced Disease         | 969 |
| Treatment of Metastatic and Recurrent Disease | 973 |
| Immunotherapy                                 | 982 |

## **SECTION 4**    *Cancer of the Liver*    986

|                                                                                         |      |
|-----------------------------------------------------------------------------------------|------|
| DAVID L. BARTLETT                                                                       |      |
| BRIAN I. CARR                                                                           |      |
| J. WALLIS MARSH                                                                         |      |
| Epidemiology                                                                            | 987  |
| Etiologic Factors                                                                       | 988  |
| Pathology                                                                               | 991  |
| Clinical Features                                                                       | 991  |
| Staging                                                                                 | 993  |
| Clinical Evaluation                                                                     | 993  |
| Screening of High-Risk Populations                                                      | 995  |
| Clinical Management                                                                     | 996  |
| Treatment of Other Primary Liver Tumors                                                 | 1003 |
| Summary: Practical Guide to the Management of Patients<br>with Hepatocellular Carcinoma | 1004 |

## **SECTION 5**    *Cancer of the Biliary Tree*    1009

|                                                     |      |
|-----------------------------------------------------|------|
| DAVID L. BARTLETT                                   |      |
| RAMESH K. RAMANATHAN                                |      |
| MELVIN DEUTSCH                                      |      |
| Cholangiocarcinomas                                 | 1009 |
| Tumors of the Gallbladder                           | 1022 |
| New Advances for Treatment of Biliary Tract Cancers | 1031 |

## **SECTION 6**    *Cancer of the Small Intestine*    1035

|                                                                                                   |      |
|---------------------------------------------------------------------------------------------------|------|
| HERBERT J. ZEH III                                                                                |      |
| Incidence                                                                                         | 1036 |
| Pathogenetic Mechanisms in Small Intestinal Carcinogenesis                                        | 1036 |
| Genetic and Environmental Factors That Predispose to Malignancy<br>Arising in the Small Intestine | 1037 |
| Presentation and Diagnosis of Cancers Arising in the Small Intestine                              | 1038 |
| Adenocarcinoma Arising in the Small Intestine                                                     | 1040 |
| Carcinoid Tumors Arising in the Small Intestine                                                   | 1042 |
| Lymphoma Arising in the Small Intestine                                                           | 1044 |
| Mesenchymal Tumors Arising in the Small Intestine                                                 | 1046 |

## **SECTION 7**    *Gastrointestinal Stromal Tumors*    1050

|                                           |      |
|-------------------------------------------|------|
| GEORGE D. DEMETRI                         |      |
| Histopathologic Features and Histogenesis | 1050 |

|                                                                                           |      |
|-------------------------------------------------------------------------------------------|------|
| Clinical Considerations                                                                   | 1052 |
| Treatment Options and Management Decisions in the Era of Molecularly Targeted Therapies f |      |
| Gastrointestinal Stromal Tumor                                                            | 1054 |
| Special Considerations in Gastrointestinal Stromal Tumor                                  | 1058 |
| New Challenges and Alternative Approaches                                                 | 1059 |

## SECTION 8 *Cancer of the Colon* 1061

|                                                          |      |
|----------------------------------------------------------|------|
| STEVEN K. LIBUTTI                                        |      |
| LEONARD B. SALTZ                                         |      |
| ANIL K. RUSTGI                                           |      |
| JOEL E. TEPPER                                           |      |
| Epidemiology                                             | 1061 |
| Etiology: Genetic and Environmental Risk Factors         | 1062 |
| Biology of Colorectal Cancer: Clinical and Molecular     |      |
| Genetic Risk Factors                                     | 1063 |
| Anatomy of the Colon                                     | 1065 |
| Diagnosis                                                | 1067 |
| Screening                                                | 1068 |
| Staging and Prognosis                                    | 1068 |
| Approaches to Surgical Resection of Colon Cancer         | 1076 |
| Polyps and Stage I Colon Cancer                          | 1080 |
| Stage II and Stage III Colon Cancer                      | 1080 |
| Surgical Management of Stage IV Disease                  | 1089 |
| Management of Unresectable Metastatic Disease            | 1089 |
| Management of Synchronous Primary and Metastatic Disease | 1102 |
| Unusual Colorectal Tumors                                | 1102 |

## SECTION 9 *Cancer of the Rectum* 1110

|                                                         |      |
|---------------------------------------------------------|------|
| STEVEN K. LIBUTTI                                       |      |
| JOEL E. TEPPER                                          |      |
| LEONARD B. SALTZ                                        |      |
| ANIL K. RUSTGI                                          |      |
| Anatomy                                                 | 1110 |
| Staging                                                 | 1111 |
| Surgery                                                 | 1113 |
| Stage I                                                 | 1113 |
| Combined Modality Therapy (Stages II and III)           | 1116 |
| Concurrent Chemotherapy                                 | 1119 |
| Management of Unresectable Primary and Locally Advanced |      |
| Disease (T4)                                            | 1120 |
| Radiation Therapy Technique                             | 1121 |
| Radiation Fields                                        | 1122 |

## SECTION 10 *Cancer of the Anal Region* 1125

|                           |      |
|---------------------------|------|
| BERNARD J. CUMMINGS       |      |
| JAFFER A. AJANI           |      |
| CAROL J. SWALLOW          |      |
| Anatomy                   | 1125 |
| Pathology                 | 1126 |
| Epidemiology              | 1126 |
| Risk Factors and Etiology | 1126 |

|                                                                                                                     |      |
|---------------------------------------------------------------------------------------------------------------------|------|
| Natural History                                                                                                     | 1127 |
| Staging                                                                                                             | 1128 |
| Prognostic Factors                                                                                                  | 1129 |
| Anal Canal Squamous Cancers                                                                                         | 1129 |
| Adenocarcinomas                                                                                                     | 1135 |
| Small Cell Cancers                                                                                                  | 1135 |
| Perianal Cancers                                                                                                    | 1135 |
| Special Considerations: Patients with Human Immunodeficiency Virus Infection/<br>Acquired Immunodeficiency Syndrome | 1136 |

# 30

## *Cancers of the Genitourinary System* ..... **1139**

### *SECTION 1 Cancer of the Kidney* 1139

W. MARSTON LINEHAN  
SUSAN E. BATES  
JAMES C. YANG

|                                     |      |
|-------------------------------------|------|
| Histologic Types of Renal Carcinoma | 1139 |
| Localized Renal Carcinoma           | 1149 |
| Metastatic Renal Carcinoma          | 1151 |

### *SECTION 2 Cancer of the Bladder, Ureter, and Renal Pelvis* 1168

WILLIAM U. SHIPLEY  
DONALD S. KAUFMAN  
W. SCOTT MCDOUGAL  
DOUGLAS M. DAHL  
M. DROR MICHAELSON  
ANTHONY L. ZIETMAN

|                                        |      |
|----------------------------------------|------|
| Epidemiology                           | 1168 |
| Screening and Early Detection          | 1169 |
| Pathology                              | 1169 |
| Molecular Tumor Markers                | 1170 |
| Cancer of the Bladder                  | 1171 |
| Cancers of the Ureter and Renal Pelvis | 1185 |

### *SECTION 3 Cancer of the Prostate* 1192

HOWARD I. SCHER  
STEVEN A. LEIBEL  
ZVI FUKS  
CARLOS CORDON-CARDO  
PETER T. SCARDINO

|                                                  |      |
|--------------------------------------------------|------|
| States and State Transitions                     | 1192 |
| Biologic Characterization and Pathology          | 1195 |
| Initial Urologic Evaluation: No Cancer Diagnosis | 1203 |
| Localized Disease                                | 1209 |
| Radiation Therapy                                | 1222 |
| Expectant Management                             | 1230 |
| Systemic Therapies                               | 1231 |
| Clinical Metastases: Castrate                    | 1241 |
| Conclusion                                       | 1250 |

**SECTION 4**    *Cancer of the Urethra and Penis*    1260

SANJAY RAZDAN  
LEONARD G. GOMELLA

**Cancer of the Male Urethra**    1260

**Carcinoma of the Female Urethra**    1261

**Cancer of the Penis**    1262

## 31

*Cancer of the Testis* ..... **1269**

GEORGE J. BOSL  
DEAN F. BAJORIN  
JOEL SHEINFELD  
ROBERT J. MOTZER  
R. S. K. CHAGANTI

**Background: Incidence**    1269

**Epidemiology**    1269

**Initial Presentation and Management**    1270

**Histology**    1270

**Staging**    1274

**Management of Clinical Stage I Disease**    1277

**Management of Clinical Stage II Disease (Low Tumor Burden)**    1281

**Management of Stage II and Stage III Disease (High Tumor Burden)**    1282

**Management of Relapse after Chemotherapy and Refractory Disease**    1286

**Treatment Sequelae**    1287

**Midline Tumors of Uncertain Histogenesis**    1289

**Other Testicular Tumors**    1289

## 32

*Gynecologic Cancers* ..... **1295**

**SECTION 1**    *Cancer of the Cervix, Vagina, and Vulva*    1295

PATRICIA J. EIFEL  
JONATHAN S. BEREK  
MAURIE A. MARKMAN

**Carcinoma of the Cervix**    1295

**Carcinoma of the Vagina**    1320

**Carcinoma of the Vulva**    1326

**SECTION 2**    *Cancers of the Uterine Body*    1341

THOMAS W. BURKE  
ARNO J. MUNDT  
FRANCO M. MUGGIA

**Endometrial Carcinoma**    1341

**Uterine Sarcomas**    1354

**SECTION 3**    *Gestational Trophoblastic Diseases*    1360

FRANCO M. MUGGIA  
THOMAS W. BURKE  
WILLIAM SMALL, JR.

**Epidemiology**    1360

|                                                     |      |
|-----------------------------------------------------|------|
| Pathology and Biology                               | 1361 |
| Clinical Diagnosis and Human Chorionic Gonadotropin | 1361 |
| Choriocarcinoma                                     | 1362 |

## SECTION 4 *Ovarian Cancer, Peritoneal Carcinoma, and Fallopian Tube Carcinoma* 1364

|                               |      |
|-------------------------------|------|
| BETH Y. KARLAN                |      |
| MAURIE A. MARKMAN             |      |
| PATRICIA J. EIFEL             |      |
| Ovarian Cancer                | 1364 |
| Borderline Tumors             | 1388 |
| Primary Peritoneal Carcinoma  | 1389 |
| Germ Cell Tumors of the Ovary | 1390 |
| Sex Cord–Stromal Tumors       | 1392 |
| Fallopian Tube Cancer         | 1393 |

# 33

## *Cancer of the Breast* ..... 1399

### SECTION 1 *Molecular Biology of Breast Cancer* 1399

|                                                                                                                |      |
|----------------------------------------------------------------------------------------------------------------|------|
| ROBERT B. DICKSON                                                                                              |      |
| RICHARD G. PESTELL                                                                                             |      |
| MARC E. LIPPMAN                                                                                                |      |
| Genetics                                                                                                       | 1399 |
| Steroid and Growth Factor Pathways of Cellular Regulation                                                      | 1402 |
| Cell Cycle and Cell Death                                                                                      | 1408 |
| Process of Malignant Progression                                                                               | 1410 |
| Implications of Molecular Biology for Tumor Prevention, Early Detection,<br>Prognosis, and Response to Therapy | 1411 |

### SECTION 2 *Malignant Tumors of the Breast* 1415

|                                                   |      |
|---------------------------------------------------|------|
| WILLIAM C. WOOD                                   |      |
| HYMAN B. MUSS                                     |      |
| LAWRENCE J. SOLIN                                 |      |
| OLUFUNMILAYO I. OLOPADE                           |      |
| Risk Factors for Breast Cancer                    | 1415 |
| Diagnosis and Biopsy                              | 1418 |
| Pathologic Classification of Tumor Types          | 1420 |
| Staging of Breast Cancer                          | 1421 |
| Prognostic and Predictive Factors                 | 1423 |
| Advising the Woman at High Risk for Breast Cancer | 1427 |
| Ductal Carcinoma <i>In Situ</i>                   | 1429 |
| Lobular Carcinoma <i>In Situ</i>                  | 1434 |
| Paget's Disease                                   | 1434 |
| Early-Stage Breast Cancer                         | 1435 |
| Locally Advanced and Inflammatory Breast Cancer   | 1450 |
| Metastatic Breast Cancer                          | 1453 |
| Breast Cancer and Pregnancy                       | 1462 |
| Bilateral Breast Cancer                           | 1464 |
| Male Breast Cancer                                | 1465 |
| Nonepithelial Neoplasms                           | 1465 |

|           |                                                                |      |
|-----------|----------------------------------------------------------------|------|
|           | Lymphoma of the Breast                                         | 1466 |
|           | Axillary Lymph Node Presentation                               | 1466 |
|           | Local and Regional Recurrence                                  | 1467 |
|           | Breast Cancer in the Elderly                                   | 1469 |
| SECTION 3 | <i>Rehabilitation after Treatment for Cancer of the Breast</i> | 1478 |
|           | JEANNE A. PETREK                                               |      |
|           | JOSEPH J. DISA                                                 |      |
|           | Delayed versus Immediate Reconstruction                        | 1478 |
|           | Prosthetic Reconstruction                                      | 1478 |
|           | Autologous Tissue Reconstruction                               | 1479 |
|           | Postmastectomy after Breast Irradiation                        | 1481 |
|           | Skin-Sparing Mastectomy with Immediate Reconstruction          | 1481 |
|           | Lymphedema                                                     | 1483 |

34

*Cancer of the Endocrine System. . . . .*1489

|           |                                                                   |      |
|-----------|-------------------------------------------------------------------|------|
| SECTION 1 | <i>Molecular Biology of Endocrine Tumors</i>                      | 1489 |
|           | TERRY C. LAIRMORE                                                 |      |
|           | JEFFREY F. MOLEY                                                  |      |
|           | Multiple Endocrine Neoplasia Syndromes                            | 1489 |
|           | Molecular Pathogenesis of Sporadic Thyroid Neoplasms              | 1495 |
|           | Genetic Abnormalities in Parathyroid Neoplasms                    | 1497 |
|           | Other Genetic Loci Implicated in Familial Hypercalcemic Syndromes | 1498 |
|           | Parathyroid Carcinoma                                             | 1499 |
|           | Genetic Abnormalities in Adrenal Neoplasms                        | 1499 |
|           | Conclusion                                                        | 1500 |

|           |                                                                           |      |
|-----------|---------------------------------------------------------------------------|------|
| SECTION 2 | <i>Thyroid Tumors</i>                                                     | 1502 |
|           | TOBIAS CARLING                                                            |      |
|           | ROBERT UDELSMAN                                                           |      |
|           | Thyroid Tumor Classification and Staging Systems                          | 1502 |
|           | Epidemiology and Demographics                                             | 1503 |
|           | Etiology and Risk Factors                                                 | 1503 |
|           | Evaluation of the Thyroid Nodule                                          | 1506 |
|           | Well-Differentiated Thyroid Carcinoma                                     | 1508 |
|           | Treatment of Well- and Intermediately Differentiated<br>Thyroid Carcinoma | 1510 |
|           | Poorly Differentiated Thyroid Carcinoma                                   | 1514 |
|           | Medullary Thyroid Carcinoma                                               | 1515 |
|           | Thyroid Lymphoma                                                          | 1517 |
|           | Metastatic Disease of the Thyroid                                         | 1518 |
|           | Thyroid Carcinoma in Children                                             | 1518 |

|           |                             |      |
|-----------|-----------------------------|------|
| SECTION 3 | <i>Parathyroid Tumors</i>   | 1521 |
|           | DOUGLAS L. FRAKER           |      |
|           | Primary Hyperparathyroidism | 1521 |
|           | Pathology                   | 1521 |
|           | Molecular Genetics          | 1522 |

Epidemiology 1522  
 Clinical Presentation 1524  
 Natural History 1524  
 Differential Diagnosis 1525  
 Treatment 1525  
 Outcome 1526

## **SECTION 4** *Adrenal Tumors 1528*

JEFFREY A. NORTON

Pathology of the Adrenal Cortex 1528  
 Clinical Presentations of Adrenal Cortical  
 Neoplasms 1529  
 Treatment of Adrenal Cortical Neoplasms 1533  
 Pheochromocytoma 1535

## **SECTION 5** *Pancreatic Endocrine Tumors 1540*

H. RICHARD ALEXANDER, JR.  
 ROBERT T. JENSEN

Pathogenesis, Pathology, Tumor Biology 1541  
 Clinical Presentation and Diagnosis 1543  
 Imaging and Localization of Pancreatic  
 Endocrine Tumors 1547  
 Treatment of Resectable Disease 1548  
 Treatment of Metastatic Disease 1555

## **SECTION 6** *Carcinoid Tumors and the Carcinoid Syndrome 1559*

ROBERT T. JENSEN  
 GERARD M. DOHERTY

Pathology and Tumor Histology 1559  
 Molecular Pathogenesis 1562  
 Clinical Features 1562  
 Carcinoid Syndrome 1563  
 Treatment of the Carcinoid Tumor 1571

## **SECTION 7** *Multiple Endocrine Neoplasias 1575*

GERARD M. DOHERTY  
 ROBERT T. JENSEN

Multiple Endocrine Neoplasia Type 1 1575  
 Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia  
 Types 2A and 2B 1578

# **35**

## *Sarcomas of the Soft Tissues and Bone . . . . . 1581*

### **SECTION 1** *Soft Tissue Sarcoma 1581*

MURRAY F. BRENNAN  
 SAMUEL SINGER  
 ROBERT G. MAKI  
 BRIAN O'SULLIVAN

Incidence 1581

|                                                                                         |      |
|-----------------------------------------------------------------------------------------|------|
| Etiology and Genetics                                                                   | 1581 |
| Distribution                                                                            | 1584 |
| Pathologic Classification                                                               | 1584 |
| Grading of Sarcoma                                                                      | 1587 |
| Differential Diagnosis                                                                  | 1588 |
| Clinicopathologic Features of Specific Types of Benign and Malignant Soft Tissue Tumors | 1589 |
| Clinical Presentation                                                                   | 1597 |
| Differential Diagnosis                                                                  | 1597 |
| Management of Extremity and Superficial Truncal Soft Tissue Sarcoma                     | 1602 |
| Radiation Therapy                                                                       | 1603 |
| Adjuvant Brachytherapy                                                                  | 1608 |
| Special Considerations                                                                  | 1609 |
| Definitive Radiation                                                                    | 1610 |
| Adjuvant Chemotherapy                                                                   | 1611 |
| Preoperative Chemotherapy                                                               | 1616 |
| Intraarterial Chemotherapy                                                              | 1617 |
| Hyperthermia and Limb Perfusion                                                         | 1617 |
| Special Features of the Management of Sarcomas of Nonextremity Sites                    | 1618 |
| Serious Complications of Primary Treatment                                              | 1620 |
| Prognostic Factors                                                                      | 1622 |
| Quality of Life and Functional Outcome                                                  | 1623 |
| Treatment of Local Recurrence                                                           | 1623 |
| Management of Advanced Disease                                                          | 1624 |
| Resection of Metastatic Disease                                                         | 1624 |
| Systemic Therapy for Advanced Disease                                                   | 1624 |
| Response by Histologic Subtype and Site                                                 | 1629 |
| Recommendations for Patients with Advanced Disease                                      | 1631 |
| Future Directions                                                                       | 1631 |

## SECTION 2 *Sarcomas of Bone* 1638

MARTIN M. MALAWER

LEE J. HELMAN

BRIAN O'SULLIVAN

|                                                        |      |
|--------------------------------------------------------|------|
| Classification and Types of Bone Tumor                 | 1638 |
| Radiographic Evaluation and Diagnosis                  | 1639 |
| Natural History                                        | 1640 |
| Staging Bone Tumors                                    | 1641 |
| Preoperative Evaluation                                | 1642 |
| Biopsy Technique and Timing                            | 1644 |
| Restaging after Induction (Preoperative) Chemotherapy  | 1645 |
| Surgical Management of Skeletal Tumors                 | 1646 |
| Principles and Techniques of Limb-Sparing Surgery      | 1647 |
| Limb-Sparing Surgery and Perioperative Pain Management | 1648 |
| Amputations                                            | 1652 |
| Cryosurgery                                            | 1652 |
| Chemotherapy for Bone Sarcomas                         | 1652 |
| Radiotherapy for Bone Tumors                           | 1658 |
| Malignant Bone Tumors                                  | 1660 |

# 36

## *Benign and Malignant Mesothelioma* . . . . . **1687**

HARVEY I. PASS

NICHOLAS J. VOGELZANG

STEPHEN M. HAHN

MICHELE CARBONE

**Mechanism of Asbestos-Induced Oncogenesis** 1687

**Mechanism of Asbestos Pathogenicity** 1688

**Overview of Molecular Mechanisms in Mesothelioma** 1688

**Simian Virus 40** 1690

**Radiation and Mesothelioma** 1690

**Genetic Predisposition to Mesothelioma** 1690

**Pathology of Mesothelioma** 1691

**Solitary Fibrous Tumors of Pleura** 1693

**Clinical Presentation of Malignant Pleural Mesothelioma** 1693

**Diagnostic Approach** 1698

**Natural History** 1699

**Prognostic Indicators** 1699

**Staging** 1700

**Treatment** 1700

**Malignant Peritoneal Mesothelioma** 1710

**Malignant Mesothelioma of the Tunica Vaginalis Testis** 1712

**Malignant Mesothelioma of the Pericardium** 1712

# 37

## *Cancer of the Skin* . . . . . **1717**

SUMAIRA Z. AASI

DAVID J. LEFFELL

**Diagnosis** 1717

**General Approach to Management of Skin Cancer** 1718

**Precancerous Lesions** 1723

**Carcinoma Metastatic to Skin** 1741

**Conclusion** 1741

# 38

## *Melanoma* . . . . . **1745**

### **SECTION 1** *Molecular Biology of Cutaneous Melanoma* 1745

ZHAO-JUN LIU

MEENHARD HERLYN

**Etiology of Melanoma** 1745

**Genetics of Melanoma** 1746

**Biologic Basis of Melanoma Development and Progression** 1749

### **SECTION 2** *Cutaneous Melanoma* 1754

CHARLES M. BALCH

MICHAEL B. ATKINS

ARTHUR J. SOBER

**Epidemiology** 1754

Anatomic Distribution 1755

Risk Factors 1756

Prevention and Screening 1757

Diagnosis of Melanoma 1759

Prognostic Factors 1760

New Staging System for Melanoma 1765

Biopsy 1769

Surgical Treatment of Primary Melanoma (Stages I to III) 1769

Local Recurrences 1774

Management of Regional Nodes—Lymphadenectomy (Stage III) 1774

Radiotherapy for Regional Metastases (Stage III) 1778

Regional Relapses 1779

Adjuvant Systemic Therapy (Stages II and III) 1780

Follow-Up of Melanoma Patients (Stages I to III) 1786

Diagnosis of Stage IV Melanoma 1786

Surgery and Irradiation for Distant Metastases (Stage IV) 1787

Systemic Treatment of Stage IV Melanoma 1792

SECTION 3    *Intraocular Melanoma*    1809

ROBERT B. AVERY

MINESH P. MEHTA

RICHARD M. AUCHTER

DANIEL M. ALBERT

Epidemiology 1809

Mortality 1810

Natural History 1810

Etiology and Pathogenesis 1811

Histopathology 1812

Diagnosis 1813

Prognostic Assessment 1815

Therapeutic Approaches 1816

Radiation Therapy 1817

Management 1823

Future Directions 1824

**39**

*Neoplasms of the Central Nervous System* . . . . . 1827

SECTION 1    *Molecular Biology of Central Nervous System Neoplasms*    1827

DAVID N. LOUIS

WEBSTER K. CAVENEE

Diffuse, Fibrillary Astrocytomas 1827

Other Gliomas 1829

Medulloblastomas 1831

Meningiomas 1831

Peripheral Nerve Tumors 1832

Miscellaneous Tumors 1832

Neurologic Tumor Syndromes 1832

Conclusion 1833

## SECTION 2 *Neoplasms of the Central Nervous System* 1834

HOWARD A. FINE  
FRED G. BARKER II  
JAMES M. MARKERT  
JAY S. LOEFFLER

**General Considerations** 1834  
**Anatomic and Clinical Considerations** 1836  
**Neurodiagnostic Tests** 1838  
**Surgery** 1841  
**Radiation Therapy** 1843  
**Chemotherapy** 1845  
**Cerebral Astrocytomas** 1847  
**Brainstem Gliomas** 1854  
**Cerebellar Astrocytomas** 1856  
**Optic, Chiasmal, and Hypothalamic Gliomas** 1856  
**Oligodendrogliomas** 1858  
**Ependymomas** 1860  
**Meningiomas** 1862  
**Primitive Neuroepithelial Tumors** 1865  
**Medulloblastomas** 1865  
**Pineal Region Tumors** 1869  
**Pituitary Adenomas** 1871  
**Craniopharyngiomas** 1873  
**Acoustic Neuromas (Vestibular Schwannomas)** 1874  
**Glomus Jugulare Tumors** 1875  
**Chordomas and Chondrosarcomas** 1876  
**Hemangioblastomas** 1877  
**Choroid Plexus Papillomas and Carcinomas** 1879  
**Spinal Axis Tumors** 1880

# 40

## *Cancers of Childhood* ..... 1889

### SECTION 1 *Molecular Biology of Childhood Cancers* 1889

LEE J. HELMAN  
DAVID MALKIN

**Tumor Suppressor Genes** 1890  
**Retinoblastoma: The Paradigm** 1890  
**Wilms' Tumor: Three Distinct Loci** 1891  
**Neurofibromatoses** 1892  
**Neuroblastoma** 1892  
**Ewing's Sarcoma Family of Tumors** 1893  
**Rhabdomyosarcoma** 1893  
**Hereditary Syndromes Associated with Tumors of Childhood** 1894  
**Predictive Testing for Germline Mutations and Childhood Cancers** 1895  
**Molecular Therapeutics** 1895

SECTION 2 Solid Tumors of Childhood 1898

- DAVID H. EBB
- DANIEL M. GREEN
- ROBERT C. SHAMBERGER
- NANCY J. TARBELL
- Epidemiology 1898
- Management of Childhood Cancer 1898
- Wilms’ Tumor 1898
- Favorable Histology Wilms’ Tumor 1903
- Neuroblastoma 1904
- Retinoblastoma 1909
- Advanced Unilateral Disease 1911
- Limited Unilateral or Limited Bilateral Disease 1911
- Bilateral Disease 1911
- Chemotherapy 1912
- Rhabdomyosarcoma 1912
- Ewing’s Sarcoma and Peripheral Primitive Neuroectodermal Tumor 1919
- Primary Hepatic Tumors 1923
- Germ Cell Tumors 1926
- Clinical Presentation and Treatment by Anatomic Site 1928

41 Lymphomas ..... 1939

SECTION 1 Leukemias and Lymphomas of Childhood 1939

- HOWARD J. WEINSTEIN
- NANCY J. TARBELL
- Leukemias 1939
- Non-Hodgkin’s Lymphoma 1948
- Hodgkin’s Disease 1953

SECTION 2 Non-Hodgkin’s Lymphomas 1957

- RICHARD I. FISHER
- PETER M. MAUCH
- NANCY LEE HARRIS
- JONATHAN W. FRIEDBERG
- Epidemiology 1957
- Etiology 1958
- Biologic Background for Classification of Lymphoid Neoplasms 1959
- Principles of the Revised European-American Classification of Lymphoid Neoplasms/World Health Organization Classification of Lymphoid Neoplasms 1967
- Principles of Management of Non-Hodgkin’s Lymphoma 1969
- Specific Disease Entities 1971
- Special Clinical Situations 1990

**SECTION 3**    *Cutaneous T-Cell Lymphomas*    1998

LYNN D. WILSON  
GLENN W. JONES  
MICHAEL GIRARDI  
RICHARD L. EDELSON  
PETER W. HEALD

**Pathobiology**    1998

**Epidemiology**    1998

**Etiology**    1998

**Clinical Presentation**    1999

**Approach to the Patient with Mycosis Fungoides**    2000

**Patient Evaluation**    2002

**Principles of Therapy**    2003

**Other Clinical Management Issues**    2010

**SECTION 4**    *Primary Central Nervous System Lymphoma*    2012

LISA M. DEANGELIS  
JOACHIM YAHALOM

**Clinical Features**    2012

**Diagnostic Tests**    2013

**Pathology**    2013

**Management and Therapy**    2014

**Immunologically Normal Patients**    2015

**Immunocompromised Patients**    2019

**SECTION 5**    *Hodgkin's Lymphoma*    2020

VOLKER DIEHL  
NANCY LEE HARRIS  
PETER M. MAUCH

**History**    2020

**Etiology and Epidemiology**    2021

**Biology and Cell of Origin**    2021

**Pathology**    2026

**Diagnosis and Staging**    2032

**Clinical Presentation**    2034

**Treatment Methods**    2035

**Choice of Treatment**    2038

**Special Cases**    2059

**Sequelae**    2062

**Quality of Life**    2064

**New Drugs for Treatment of Hodgkin's Lymphoma**    2064

**Immunotherapy**    2065

**Gene Therapy**    2068

**42***Acute Leukemias* . . . . . **2077****SECTION 1**    *Molecular Biology of Acute Leukemias*    2077

D. GARY GILLILAND  
GLEN DAVID RAFFEL

**Leukemic Stem Cell**    2077

|                                                                                       |      |
|---------------------------------------------------------------------------------------|------|
| Recurring Chromosomal Abnormalities in Acute Leukemia                                 | 2078 |
| Deletions and Numeric Abnormalities in Acute Leukemias                                | 2083 |
| Chromosomal Translocations That Result in Overexpression of<br>Otherwise Normal Genes | 2084 |
| Point Mutations in Acute Leukemia                                                     | 2084 |
| Mutational Complementation Groups in Acute Leukemias                                  | 2085 |
| Conclusion                                                                            | 2086 |

## **SECTION 2**    *Management of Acute Leukemias*    2088

DAVID A. SCHEINBERG  
PETER G. MASLAK  
MARK A. WEISS

|                                                                    |      |
|--------------------------------------------------------------------|------|
| Epidemiology and Etiology                                          | 2088 |
| Biology of Acute Leukemias                                         | 2090 |
| Diagnosis and Classification of Acute Leukemias                    | 2091 |
| Principles of Clinical Management of Acute Myelogenous<br>Leukemia | 2098 |
| Treatment of Newly Diagnosed Acute Myelogenous<br>Leukemia         | 2100 |
| Induction                                                          | 2100 |
| Treatment of Relapsed Acute Myelogenous<br>Leukemia                | 2106 |
| Conclusion                                                         | 2115 |

# 43

## *Chronic Leukemias* . . . . . 2121

### **SECTION 1**    *Chronic Myelogenous Leukemia*    2121

|                                     |      |
|-------------------------------------|------|
| BRIAN J. DRUKER<br>STEPHANIE J. LEE |      |
| Epidemiology                        | 2121 |
| Pathogenesis                        | 2121 |
| Diagnosis and Clinical Course       | 2123 |
| Treatment of Chronic-Phase Disease  | 2124 |
| Advanced-Phase Disease              | 2130 |
| Future Directions                   | 2131 |

### **SECTION 2**    *Chronic Lymphoid Leukemias*    2133

|                                        |      |
|----------------------------------------|------|
| SUSAN O'BRIEN<br>MICHAEL J. KEATING    |      |
| Molecular Biology                      | 2133 |
| Immune Abnormalities                   | 2135 |
| Diagnosis                              | 2135 |
| Clinical Manifestations                | 2135 |
| Treatment and Response Criteria        | 2138 |
| Biologic Therapies                     | 2140 |
| Second Malignancies and Transformation | 2141 |
| Prolymphocytic Leukemia                | 2142 |
| Large Granular Lymphocyte Leukemia     | 2142 |
| Hairy Cell Leukemia                    | 2142 |

# SECTION 3 *Myelodysplastic Syndromes* 2144

|                                                                 |      |
|-----------------------------------------------------------------|------|
| STEFAN FADERL                                                   |      |
| HAGOP M. KANTARJIAN                                             |      |
| <b>Incidence and Epidemiology</b>                               | 2144 |
| <b>Etiology</b>                                                 | 2144 |
| <b>Classification and Prognostic Factors</b>                    | 2145 |
| <b>Biology and Pathophysiology of Myelodysplastic Syndromes</b> | 2146 |
| <b>Clinical Manifestations</b>                                  | 2148 |
| <b>Laboratory Features</b>                                      | 2148 |
| <b>Differential Diagnosis</b>                                   | 2148 |
| <b>Subtypes of Myelodysplastic Syndromes</b>                    | 2148 |
| <b>Therapy of Myelodysplastic Syndromes</b>                     | 2149 |
| <b>Conclusion</b>                                               | 2153 |

# 44 *Plasma Cell Neoplasms* . . . . . 2155

|                                         |      |
|-----------------------------------------|------|
| NIKHIL C. MUNSHI                        |      |
| KENNETH C. ANDERSON                     |      |
| <b>History</b>                          | 2155 |
| <b>Epidemiology</b>                     | 2156 |
| <b>Etiology: Environmental Exposure</b> | 2156 |
| <b>Pathogenesis</b>                     | 2157 |
| <b>Clinical Manifestations</b>          | 2163 |
| <b>Diagnosis</b>                        | 2165 |
| <b>Differential Diagnosis</b>           | 2168 |
| <b>Prognostic Variables</b>             | 2170 |
| <b>Treatment</b>                        | 2172 |
| <b>Waldenström's Macroglobulinemia</b>  | 2181 |

# 45 *Paraneoplastic Syndromes* . . . . . 2189

|                                                  |      |
|--------------------------------------------------|------|
| SUSANNE M. ARNOLD                                |      |
| FRANK S. LIEBERMAN                               |      |
| KENNETH A. FOON                                  |      |
| <b>Endocrinologic Manifestations of Cancer</b>   | 2189 |
| <b>Hematologic Manifestations of Cancer</b>      | 2193 |
| <b>Gastrointestinal Manifestations of Cancer</b> | 2196 |
| <b>Renal Manifestations of Nonrenal Cancer</b>   | 2197 |
| <b>Cutaneous Manifestations of Cancer</b>        | 2197 |
| <b>Neurologic Manifestations of Cancer</b>       | 2200 |
| <b>Miscellaneous Paraneoplastic Syndromes</b>    | 2207 |

# 46 *Cancer of Unknown Primary Site* . . . . . 2213

|                                                                |      |
|----------------------------------------------------------------|------|
| F. ANTHONY GRECO                                               |      |
| JOHN D. HAINSWORTH                                             |      |
| <b>Poorly Differentiated Neoplasms of Unknown Primary Site</b> | 2214 |

**Poorly Differentiated Carcinoma (with or without Features of Adenocarcinoma)  
of Unknown Primary Site**    2216

**Neuroendocrine Carcinoma of Unknown Primary Site**    2221

**Adenocarcinoma of Unknown Primary Site**    2222

**Squamous Carcinoma of Unknown Primary Site**    2225

**Chemotherapy for Metastatic Carcinoma of Unknown Primary Site**    2226

**Special Issues in Carcinoma of Unknown Primary Site**    2229

**Conclusion**    2232

**47**

***Peritoneal Carcinomatosis* . . . . .**    **2237**

JAMES F. PINGPANK, JR.

**Pathophysiology**    2237

**Diagnostic Evaluation**    2238

**Histologic Subtypes**    2238

**Treatment**    2242

**48**

***Immunosuppression-Related Malignancies* . . . . .**    **2247**

**SECTION 1    *AIDS-Related Malignancies*    2247**

ROBERT YARCHOAN

RICHARD F. LITTLE

**Kaposi's Sarcoma**    2247

**AIDS-Associated Lymphomas**    2253

**Primary Central Nervous System Lymphoma in AIDS**    2258

**Hodgkin's Disease**    2259

**Anogenital Cancers in Human Immunodeficiency Virus  
Infection**    2259

**Future Directions**    2260

**SECTION 2    *Transplantation-Related Malignancies*    2263**

STANLEY R. RIDDELL

**Immune Surveillance and Tumor Development**    2263

**Hematopoietic Stem Cell Transplant Recipients**    2263

**Organ Transplant Recipients**    2267

**49**

***Oncologic Emergencies* . . . . .**    **2273**

**SECTION 1    *Superior Vena Cava Syndrome*    2273**

JOACHIM YAHALOM

**Anatomy and Pathophysiology**    2273

**Etiology and Natural History**    2273

**Diagnostic Procedures**    2275

**Management**    2276

Treatment 2277

Recommendations 2279

**SECTION 2** *Increased Intracranial Pressure* 2281

JOACHIM M. BAEHRING

Pathophysiologic Considerations 2281

Epidemiology and Pathogenesis 2281

Clinical Presentation 2282

Diagnosis 2284

Treatment 2286

**SECTION 3** *Spinal Cord Compression* 2287

JOACHIM M. BAEHRING

Epidemiology 2287

Pathophysiology 2287

Clinical Presentation 2289

Differential Diagnosis 2290

Diagnosis 2290

Treatment 2291

Prognosis 2291

Conclusion 2292

**SECTION 4** *Metabolic Emergencies* 2292

ANTONIO TITO FOJO

Tumor Lysis Syndrome 2292

Hyperuricemia 2294

Cancer and Hyponatremia 2295

Lactic Acidosis and Cancer 2296

Hypercalcemia and Cancer 2297

Cancer-Related Hemolytic-Uremic Syndrome 2299

**SECTION 5** *Urologic Emergencies* 2301

JONATHAN A. COLEMAN

MCCLELLAN M. WALTHER

Urinary Tract Infection 2301

Cystitis 2301

Bladder Hemorrhage 2304

Urinary Obstruction 2305

Priapism 2307

Paraphimosis 2307

**50***Specialized Techniques in Cancer Management. . . . .* **2309****SECTION 1** *Vascular Access and Specialized Techniques of Drug Delivery* 2309

JAMES F. PINGPANK, JR.

Catheter Types 2309

|                                |      |
|--------------------------------|------|
| Catheter Selection             | 2312 |
| Insertion Techniques           | 2312 |
| Catheter-Related Complications | 2314 |

|                  |                                              |             |
|------------------|----------------------------------------------|-------------|
| <b>SECTION 2</b> | <b><i>Isolation Perfusion</i></b>            | <b>2316</b> |
|                  | H. RICHARD ALEXANDER, JR.                    |             |
|                  | Principles of Isolation Perfusion            | 2316        |
|                  | Results of Isolation Perfusion               | 2318        |
|                  | Current Status of Isolated Limb Perfusion    | 2319        |
|                  | Current Status of Isolated Hepatic Perfusion | 2321        |
|                  | Status of Isolation Perfusion of Other Sites | 2321        |
|                  | Variations of Isolation Perfusion Techniques | 2321        |
|                  | Conclusion                                   | 2321        |

# 51

|                                                 |             |
|-------------------------------------------------|-------------|
| <i>Treatment of Metastatic Cancer</i> . . . . . | <b>2323</b> |
|-------------------------------------------------|-------------|

|                  |                                       |             |
|------------------|---------------------------------------|-------------|
| <b>SECTION 1</b> | <b><i>Metastatic Brain Cancer</i></b> | <b>2323</b> |
|                  | DAVID A. LARSON                       |             |
|                  | JAMES L. RUBENSTEIN                   |             |
|                  | MICHAEL W. MCDERMOTT                  |             |
|                  | Brain Metastases                      | 2323        |
|                  | Carcinomatous Meningitis              | 2333        |

|                  |                                             |             |
|------------------|---------------------------------------------|-------------|
| <b>SECTION 2</b> | <b><i>Metastatic Cancer to the Lung</i></b> | <b>2337</b> |
|                  | MICHAEL R. JOHNSTON                         |             |
|                  | MARC DE PERROT                              |             |
|                  | Biology                                     | 2337        |
|                  | Diagnosis                                   | 2337        |
|                  | Treatment                                   | 2339        |
|                  | Results                                     | 2346        |

|                  |                                                                    |             |
|------------------|--------------------------------------------------------------------|-------------|
| <b>SECTION 3</b> | <b><i>Metastatic Cancer to the Liver</i></b>                       | <b>2352</b> |
|                  | H. RICHARD ALEXANDER, JR.                                          |             |
|                  | NANCY E. KEMENY                                                    |             |
|                  | THEODORE S. LAWRENCE                                               |             |
|                  | Natural History of Liver Metastases                                | 2353        |
|                  | Imaging of Hepatic Metastases                                      | 2354        |
|                  | Resection: Technical Considerations                                | 2354        |
|                  | Results of Hepatic Resection for Colorectal Cancer                 | 2355        |
|                  | Results of Resection for Noncolorectal Cancers                     | 2355        |
|                  | Hepatic Arterial Chemotherapy                                      | 2356        |
|                  | Toxicity of Hepatic Arterial Infusion Therapy with<br>Floxuridine  | 2358        |
|                  | Other Agents Used with Hepatic Arterial Infusion                   | 2359        |
|                  | Adjuvant Therapy after Resection of Colorectal<br>Liver Metastases | 2359        |
|                  | Neoadjuvant Chemotherapy                                           | 2360        |
|                  | Other Liver Tumors                                                 | 2360        |

|                                                        |      |
|--------------------------------------------------------|------|
| Hepatic Artery Infusion with Hepatic Venous Filtration | 2360 |
| Isolated Hepatic Perfusion                             | 2361 |
| Chemoembolization for Metastatic Cancer to the Liver   | 2361 |
| Local Ablative Therapy                                 | 2362 |
| Cryotherapy                                            | 2363 |
| Radiofrequency Ablation                                | 2363 |
| Other Ablative Techniques                              | 2364 |
| Results of Whole Liver Irradiation $\pm$ Chemotherapy  | 2365 |
| Conclusion                                             | 2366 |

## **SECTION 4**    *Metastatic Cancer to the Bone*    2368

MARK W. MANOSO  
JOHN H. HEALEY

|                         |      |
|-------------------------|------|
| Presentation            | 2368 |
| Pathophysiology         | 2369 |
| Diagnostic Evaluation   | 2369 |
| Imaging of Bone Lesions | 2370 |
| Therapeutic Goals       | 2371 |
| Therapeutic Modalities  | 2371 |

## **SECTION 5**    *Malignant Pleural and Pericardial Effusions*    2381

DAO M. NGUYEN  
DAVID S. SCHRUMP

|                                |      |
|--------------------------------|------|
| Malignant Pleural Effusion     | 2381 |
| Malignant Pericardial Effusion | 2387 |

## **SECTION 6**    *Malignant Ascites*    2392

RICHARD B. HOSTETTER  
FRANCESCO M. MARINCOLA  
DOUGLAS J. SCHWARTZENTRUBER

|                                |      |
|--------------------------------|------|
| Diagnosis and Workup           | 2392 |
| Treatment of Malignant Ascites | 2393 |
| Conclusion                     | 2396 |

# 52

## *Hematopoietic Therapy* . . . . . 2399

### **SECTION 1**    *Transfusion Therapy*    2399

YANYUN WU  
PETER L. PERROTTA  
EDWARD L. SNYDER

|                                                    |      |
|----------------------------------------------------|------|
| Blood Component Therapy                            | 2400 |
| Transfusion Reactions and Complications            | 2406 |
| Transfusion-Transmitted Disease                    | 2409 |
| Use of Special Blood Products in Oncology Patients | 2410 |
| Apheresis                                          | 2411 |
| Effect of Growth Factors on Transfusion Medicine   | 2412 |
| Blood Substitutes                                  | 2412 |

|                      |                                                                                         |                 |
|----------------------|-----------------------------------------------------------------------------------------|-----------------|
| <b>SECTION 2</b>     | <b><i>Autologous Stem Cell Transplantation</i></b>                                      | <b>2414</b>     |
|                      | DENNIS L. COOPER<br>STUART SEROPIAN                                                     |                 |
|                      | History                                                                                 | 2415            |
|                      | Stem Cell Mobilization                                                                  | 2415            |
|                      | Inadequate Mobilization of Stem Cells                                                   | 2416            |
|                      | Tumor Contamination                                                                     | 2418            |
|                      | Practical Considerations for the Potential Autologous Stem Cell Patient                 | 2419            |
|                      | High-Dose Therapy Regimens: New Directions                                              | 2419            |
|                      | Late Toxicity: Myelodysplasia and Secondary Leukemia                                    | 2421            |
|                      | Future Directions                                                                       | 2421            |
| <br><b>SECTION 3</b> | <br><b><i>Allogeneic Hematopoietic Stem Cell Transplantation</i></b>                    | <br><b>2423</b> |
|                      | RICHARD W. CHILDS                                                                       |                 |
|                      | Conditioning Regimens                                                                   | 2424            |
|                      | Graft-Versus-Leukemia Effect                                                            | 2425            |
|                      | Mechanisms of Graft-Versus-Leukemia Effect                                              | 2427            |
|                      | Complications of Allogeneic Hematopoietic Stem Cell Transplantation                     | 2427            |
|                      | Epstein-Barr Virus Lymphoproliferative Disorder                                         | 2429            |
|                      | Sources of Allogeneic Hematopoietic Stem Cells                                          | 2432            |
|                      | Results of Conventional Allogeneic Transplantation for Hematologic Malignancies         | 2434            |
|                      | Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation                          | 2435            |
|                      | Future Prospects                                                                        | 2439            |
| <br><b>SECTION 4</b> | <br><b><i>Hematopoietic Growth Factors</i></b>                                          | <br><b>2442</b> |
|                      | JENNIFER L. HOLTER<br>HOWARD OZER                                                       |                 |
|                      | Overview of Hematopoiesis and Hematopoietic Growth Factors                              | 2442            |
|                      | Clinical Use of Recombinant Erythropoietin in Cancer Therapy                            | 2448            |
|                      | Anemia Related to Myeloproliferative Disorders                                          | 2450            |
|                      | Predictors of Recombinant Erythropoietin Therapy Response                               | 2451            |
|                      | Clinical Use of Recombinant Granulocyte Colony-Stimulating Factors<br>in Cancer Therapy | 2452            |
|                      | Clinical Use of Recombinant Interleukin-11 in Cancer Therapy                            | 2455            |
|                      | Hematopoietic Growth Factors in Development                                             | 2456            |
|                      | Conclusion                                                                              | 2456            |
| <br><b>53</b>        | <br><b><i>Infections in the Cancer Patient</i></b>                                      | <br><b>2461</b> |
|                      | BRAHM H. SEGAL<br>THOMAS J. WALSH<br>JUAN C. GEA-BANACLOCHE<br>STEVEN M. HOLLAND        |                 |
|                      | Factors Predisposing Cancer Patients to Infection                                       | 2461            |
|                      | Bacterial Infections in Cancer Patients                                                 | 2465            |
|                      | Fungal Infections                                                                       | 2469            |
|                      | Viral Infections                                                                        | 2477            |
|                      | Parasitic Infections                                                                    | 2484            |

Neutropenic Fever 2486  
 Syndromes 2496  
 Immune Augmentation Strategies 2506

# 54

## *Adverse Effects of Treatment. . . . . 2515*

### *SECTION 1 Nausea and Vomiting 2515*

ANN M. BERGER  
 REBECCA A. CLARK-SNOW  
 Nature of the Problem 2515  
 Pathophysiology of Nausea and Vomiting 2515  
 Emetic Syndromes 2517  
 Control of Emesis and Risk Factors 2518  
 Antiemetic Agents 2519  
 Treatment Options Based on Emesis Category 2520  
 New Agents 2520  
 Radiation-Induced Nausea and Vomiting 2521  
 Nausea and Vomiting Secondary to Comorbid Conditions 2522  
 Improving Antiemetic Control 2522

### *SECTION 2 Oral Complications 2523*

ANN M. BERGER  
 JANE M. FALL-DICKSON  
 Oral Complications 2523  
 Sequelae of Oral Complications 2525  
 Strategies for Prevention and Treatment of Oral Complications 2526  
 Future Research Directions 2533  
 Conclusion 2533

### *SECTION 3 Pulmonary Toxicity 2535*

DIANE E. STOVER  
 ROBERT J. KANER  
 Radiation-Induced Pulmonary Toxicity 2535  
 Radiation-Related Bronchiolitis Obliterans with Organizing Pneumonia 2538  
 Chemotherapy-Induced Pulmonary Toxicity 2539

### *SECTION 4 Cardiac Toxicity 2545*

JOACHIM YAHALOM  
 CAROL S. PORTLOCK  
 Anthracyclines 2545  
 Mitoxantrone 2547  
 Cyclophosphamide 2547  
 Ifosfamide 2547  
 Taxanes 2547  
 Trastuzumab 2548  
 Fluoropyrimidines 2549  
 Radiation-Induced Heart Disease 2549  
 Conclusion 2553

**SECTION 5**    *Hair Loss*    2556

ANN M. BERGER  
JOYSON KARAKUNNEL

**Anatomy and Physiology**    2556

**Classification**    2556

**Staging**    2557

**Diagnosis**    2557

**Treatment**    2557

**Conclusion**    2559

**SECTION 6**    *Gonadal Dysfunction*    2560

MARVIN L. MEISTRICH  
RENA VASSILOPOULOU-SELLIN  
LARRY I. LIPSHULTZ

**Effects of Cytotoxic Agents on Adult Men**    2560

**Effects of Cytotoxic Agents on Adult Women**    2563

**Effects of Cytotoxic Agents on Children**    2566

**Gonadal Dysfunction after Cranial Irradiation**    2566

**Preservation of Fertility, Hormone Levels, and Sexual Function**    2567

**Prevention and Management of Erectile and Ejaculatory Dysfunction**    2570

**Genetic Concerns**    2571

**Counseling**    2572

**SECTION 7**    *Second Cancers*    2575

FLORA E. VAN LEEUWEN  
LOIS B. TRAVIS

**Methods to Assess Second Cancer Risk**    2575

**Carcinogenicity of Individual Treatment Modalities**    2576

**Risk of Second Malignancy in Patients with Selected Primary Cancers**    2580

**Conclusion**    2598

**SECTION 8**    *Miscellaneous Toxicities*    2602

RAYMOND B. WEISS

**Neurotoxicity**    2603

**Nephrotoxicity**    2607

**Hepatotoxicity**    2610

**Hypersensitivity Reactions**    2611

**Vascular Toxicity**    2612

# 55

*Supportive Care and Quality of Life* ..... **2615**

**SECTION 1**    *Management of Cancer Pain*    2615

KATHLEEN M. FOLEY

**Epidemiology**    2615

**Barriers to Cancer Pain Management**    2616

**Definition of Pain**    2617

**Anatomy and Physiology of Pain**    2617

**Types of Pain**    2618

**Temporal Aspects of Pain**    2619

|                                             |      |
|---------------------------------------------|------|
| Intensity of Pain                           | 2619 |
| Measurement of Pain                         | 2619 |
| Classification of Patients with Cancer Pain | 2621 |
| Common Pain Syndromes                       | 2624 |
| Clinical Assessment of Pain                 | 2624 |
| Management of Cancer Pain                   | 2627 |
| Analgesic Drug Therapy                      | 2627 |
| Classes of Drugs                            | 2630 |
| Psychological Approaches                    | 2639 |
| Anesthetic and Neurosurgical Approaches     | 2639 |
| Physiatric Approaches                       | 2645 |
| Sedation in the Imminently Dying            | 2645 |
| Algorithm for Cancer Pain Management        | 2646 |
| Future Directions                           | 2646 |

## **SECTION 2**   *Nutritional Support*   2649

J. STANLEY SMITH  
DAVID FRANKENFIELD  
WILEY W. SOUBA

|                                                                                      |      |
|--------------------------------------------------------------------------------------|------|
| Dysgeusia                                                                            | 2649 |
| Weight Loss and Cancer Cachexia                                                      | 2650 |
| Nutrition Support for Weight Loss and Cancer Cachexia                                | 2651 |
| Nutrition and Tumor Growth                                                           | 2651 |
| Nutritional Assessment of the Cancer Patient                                         | 2652 |
| Indications for Nutrition Support                                                    | 2652 |
| Parenteral versus Enteral Nutrition in Cancer Patients                               | 2652 |
| Specific Indications for the Use of Total Parenteral Nutrition in the Cancer Patient | 2653 |
| Improving the Efficacy of Current Feeding Regimens                                   | 2658 |
| Techniques of Providing Nutritional Support                                          | 2659 |
| Conclusion                                                                           | 2661 |

## **SECTION 3**   *Sexual Problems*   2662

PATRICIA A. GANZ  
MARK S. LITWIN  
BETH E. MEYEROWITZ

|                                                                   |      |
|-------------------------------------------------------------------|------|
| Sexual Health and Physiology                                      | 2662 |
| Sexual Problems and Their Prevalence among the General Population | 2663 |
| Impact of Cancer and Its Treatment on Sexual Health               | 2664 |
| Specific Treatments                                               | 2665 |
| Sexual Problems Associated with Specific Cancers                  | 2668 |
| Strategies for Assessment and Intervention                        | 2671 |
| Conclusion                                                        | 2673 |

## **SECTION 4**   *Genetic Counseling*   2676

ELLEN T. MATLOFF

|                                                     |      |
|-----------------------------------------------------|------|
| Why Is Cancer Genetic Counseling Necessary?         | 2676 |
| Who Is a Candidate for Cancer Genetic Counseling?   | 2677 |
| Components of the Cancer Genetic Counseling Session | 2677 |
| Issues in Cancer Genetic Counseling                 | 2680 |
| Future Directions                                   | 2681 |

|                  |                                                      |             |
|------------------|------------------------------------------------------|-------------|
| <b>SECTION 5</b> | <b><i>Psychological Issues</i></b>                   | <b>2683</b> |
|                  | BETH L. DINOFF                                       |             |
|                  | JOHN L. SHUSTER                                      |             |
|                  | Phases of Illness                                    | 2683        |
|                  | Psychological Complications of Cancer                | 2685        |
|                  | Therapies                                            | 2688        |
| <br>             |                                                      |             |
| <b>SECTION 6</b> | <b><i>Community Resources</i></b>                    | <b>2691</b> |
|                  | BONNIE A. INDECK                                     |             |
|                  | Initial Diagnosis of Cancer                          | 2691        |
|                  | Social Support Network                               | 2691        |
|                  | Emotional Support                                    | 2691        |
|                  | Information Support                                  | 2693        |
|                  | Internet                                             | 2693        |
|                  | Computer Groups                                      | 2694        |
|                  | Instrumental Support                                 | 2694        |
|                  | Trends Affecting Demand for Community Services       | 2695        |
|                  | Survivorship                                         | 2696        |
|                  | Appendix: Common Community Resources                 | 2696        |
| <br>             |                                                      |             |
| <b>SECTION 7</b> | <b><i>Specialized Care of the Terminally Ill</i></b> | <b>2702</b> |
|                  | JANET L. ABRAHM                                      |             |
|                  | Discussing Prognosis                                 | 2702        |
|                  | Advance Care Planning                                | 2703        |
|                  | Hope                                                 | 2703        |
|                  | Barriers That Inhibit Advance Care Planning          |             |
|                  | Discussions                                          | 2704        |
|                  | Curiosity                                            | 2704        |
|                  | Healing versus Curing                                | 2704        |
|                  | How to Tell the Children                             | 2704        |
|                  | Cultural/Religious Considerations                    | 2705        |
|                  | Care without Chemotherapy                            | 2706        |
|                  | Palliative Care Program                              | 2706        |
|                  | Hospice Programs                                     | 2707        |
|                  | Relief of Suffering                                  | 2708        |
|                  | The Final Days                                       | 2714        |
|                  | After the Death                                      | 2715        |
|                  | Grief and Bereavement                                | 2715        |
|                  | Conclusion                                           | 2717        |

|                                                     |             |
|-----------------------------------------------------|-------------|
| <b>56</b>                                           |             |
| <b><i>Rehabilitation of the Cancer Patient.</i></b> | <b>2719</b> |
| LYNN H. GERBER                                      |             |
| MARY M. VARGO                                       |             |
| REBECCA G. SMITH                                    |             |
| Impact of Cancer Treatment on Function              | 2720        |
| Rehabilitation Interventions                        | 2725        |

Rehabilitation Hospitalization and Basic Functional Independence 2732

Vocational Issues 2733

Rehabilitation Treatments of Specific Tumors 2734

# 57

*Societal Issues in Oncology* . . . . . **2747**

## **SECTION 1** *Ethical Issues* 2747

CHRISTOPHER K. DAUGHERTY

Ethical Issues in Clinical Care in Oncology 2747

Ethical Issues in Cancer Clinical Trials 2752

Conclusion 2757

## **SECTION 2** *Economic Issues* 2759

ALBERT B. EINSTEIN, JR.

U.S. Health Care Economy 2759

Medicare Cost-Containment Efforts 2759

Medicare Reimbursement for Cancer Services 2760

Medicaid Cost-Containment Efforts 2761

Insurance Industry Cost-Containment Efforts 2761

Hospital Economic Issues 2762

Physician Economic Issues 2762

National Cancer Institute–Designated and University Cancer Centers

Economic Issues 2763

Clinical Research 2763

Impact of Genomics 2764

Complementary and Alternative Medicine 2765

Standardization of Practice 2765

Health Economics and the Economic Burden of Cancer 2765

The Future 2766

## **SECTION 3** *Regulatory Issues* 2767

GRANT A. WILLIAMS

PATRICIA KEEGAN

NEIL R. P. OGDEN

RICHARD PAZDUR

ROBERT TEMPLE

MARK MCCLELLAN

History of U.S. Food and Drug Administration Regulation of Drugs  
and Biologics 2767

U.S. Food and Drug Administration Oversight of Clinical Trials for  
Drugs and Biologics 2768

Basis for Cancer Drug Approval 2769

Drug Safety Reporting and Evaluation 2773

Access to Investigational Drugs 2773

Biologic Drug Products: Special Considerations 2773

Regulation of Devices for Cancer Treatment and Diagnosis 2774

U.S. Food and Drug Administration Initiatives and Guidances Expediting  
Approval of Cancer Drugs, Biologics, and Devices 2776

## SECTION 4 *Telemedicine* 2777

RICHARD M. SATAVA  
JONATHAN D. LINKOUS  
JAY H. SANDERS

- Applications of Telemedicine 2778
- Telemedicine in Other Countries 2779
- Telemedicine in Oncology Care—Current Practices 2779
- Telesurgery 2779
- Telemedicine Impact on National Medical Policy 2780
- Barriers and Challenges 2780
- Conclusion 2781

## SECTION 5 *International Differences in Oncology* 2782

OLIVIER RIXE  
PETER HARPER  
DAVID KHAYAT

- Developing Nations 2782
- Cancers and Mortality: Differences in the More Developed Countries 2782
- Screening 2783
- Anticancer Drug Development throughout the World 2784
- Drug Approval Process 2784
- Cancer Treatment Strategy: European and United States Differences 2784
- Differences in Cancer Survival 2784
- Access to Cancer Care in Developed Nations 2785
- Training as an Oncologist 2786
- Research 2786
- “Truth Telling”: Differences between Nations 2786
- Cancer in the Elderly 2787
- Conclusion 2787

## SECTION 6 *The National Cancer Program* 2788

ANDREW C. VON ESCHENBACH

- National Cancer Institute as Steward of the National Cancer Program 2789
- Harnessing the Power of Molecular Epidemiology 2789
- Developing an Integrative Understanding of Cancer Biology 2790
- Providing Bioinformatics Infrastructure 2790
- Developing Prevention, Early Detection, and Prediction Approaches 2790
- Facilitating the Development of Cancer Interventions 2791
- Creating an Integrated Clinical Trials System 2791
- Overcoming Health Disparities 2791
- A Critical “Enterprise-Wide” Opportunity: Technology Development and Integration 2792
- Integrative Computational Biology and Bioinformatics 2792
- Advanced Imaging 2792
- Bioengineering and Advanced Prototyping 2792
- Development and Preclinical Testing of Prevention and Therapeutic Agents 2792
- Shared Research Resources 2793
- Conclusion 2793

# 58

|                                              |             |
|----------------------------------------------|-------------|
| <i>Information Systems in Oncology</i> ..... | <b>2795</b> |
|----------------------------------------------|-------------|

DANIEL R. MASYS

**The Internet** 2796

**Electronic Medical Records** 2799

**Conclusion** 2802

# 59

|                                                                                   |             |
|-----------------------------------------------------------------------------------|-------------|
| <i>Complementary, Alternative, and Integrative Therapies in Cancer Care</i> ..... | <b>2805</b> |
|-----------------------------------------------------------------------------------|-------------|

ETHAN M. BASCH

CATHERINE E. ULBRICHT

**Background** 2805

**Safety Concerns** 2806

**Patient–Clinician Communication** 2808

**Specific Complementary and Alternative Medicine Therapies** 2809

**Therapies Used for Cancer Treatment and Secondary Prevention** 2809

**Therapies Used for Supportive Care** 2812

**Therapies Used for Primary Cancer Prevention** 2813

## PART 4

## NEWER APPROACHES IN CANCER TREATMENT

# 60

|                           |             |
|---------------------------|-------------|
| <i>Gene Therapy</i> ..... | <b>2819</b> |
|---------------------------|-------------|

PATRICK HWU

**Methods of Gene Transfer** 2819

**Gene Marking Studies** 2824

**Genetic Modification of the Immune Response** 2826

**Modification of Tumors with Genes That Have Direct Antitumor Effects** 2830

**Selective Replication of Virus in Tumors** 2832

**Introduction of Genes into Normal Tissues to Protect Them from Chemotherapy or Radiotherapy** 2832

**Antiangiogenic Gene Therapy** 2833

**Molecular Imaging of Gene-Modified Cells** 2834

**Conclusion** 2834

# 61

|                              |             |
|------------------------------|-------------|
| <i>Cancer Vaccines</i> ..... | <b>2839</b> |
|------------------------------|-------------|

**SECTION 1 Preventive Vaccines** 2839

DOUGLAS R. LOWY

JOHN T. SCHILLER

**Background** 2839

|                                                    |      |
|----------------------------------------------------|------|
| <b>Infectious Agents and Cancer</b>                | 2839 |
| <b>Prophylactic versus Therapeutic Vaccination</b> | 2841 |
| <b>Hepatitis B Virus</b>                           | 2842 |
| <b>Human Papillomavirus</b>                        | 2843 |
| <b><i>Helicobacter pylori</i></b>                  | 2845 |

## **SECTION 2    *Therapeutic Vaccines*    2846**

|                                                                                                                  |      |
|------------------------------------------------------------------------------------------------------------------|------|
| <b>NICHOLAS P. RESTIFO</b>                                                                                       |      |
| <b>JONATHAN J. LEWIS</b>                                                                                         |      |
| <b>Elicitation of Tumor-Specific Immune Responses</b>                                                            | 2846 |
| <b>Identification of Tumor-Associated Antigens Suitable for<br/>Therapeutic Targeting</b>                        | 2846 |
| <b>Enhancement of Tumor Antigen Immunogenicity by Modification of<br/>Epitope Sequences</b>                      | 2847 |
| <b>Early Models Using Therapeutic Cancer Vaccines</b>                                                            | 2848 |
| <b>Consistent Increases in Tumor-Specific T Cells without Consistent<br/>Clinical Responses</b>                  | 2848 |
| <b>How Are We Doing in Clinical Trials?</b>                                                                      | 2848 |
| <b>Lessons from Melanoma</b>                                                                                     | 2849 |
| <b>Clinical Trial Data</b>                                                                                       | 2850 |
| <b>Immune Responses Do Not Always Translate into Clinical Responses—<br/>Proposed Mechanisms of Tumor Escape</b> | 2853 |
| <b>Future Directions: A Focus on T-Cell Activation and Death</b>                                                 | 2853 |
| <b>Conclusion</b>                                                                                                | 2854 |

# **62**

## ***Cell Transfer Therapy* . . . . . 2857**

**MARK E. DUDLEY**  
**STEVEN A. ROSENBERG**

|                                                                                                        |      |
|--------------------------------------------------------------------------------------------------------|------|
| <b>Background</b>                                                                                      | 2857 |
| <b>Preclinical Studies of Adoptive Cell Transfer</b>                                                   | 2858 |
| <b>Clinical Trials</b>                                                                                 | 2858 |
| <b>Tumor-Infiltrating Lymphocytes</b>                                                                  | 2860 |
| <b>Adoptive Cell Transfer Therapy after Lymphodepleting Chemotherapy in Patients<br/>with Melanoma</b> | 2860 |
| <b>Additional Studies</b>                                                                              | 2862 |

# **63**

## ***Antiangiogenesis Agents* . . . . . 2865**

**JUDAH FOLKMAN**

|                                                       |      |
|-------------------------------------------------------|------|
| <b>Angiogenic Switch</b>                              | 2865 |
| <b>Endogenous Angiogenesis Inhibitors</b>             | 2867 |
| <b>Rationale for Antiangiogenic Therapy of Cancer</b> | 2867 |
| <b>Antiangiogenic (Metronomic) Chemotherapy</b>       | 2869 |
| <b>Future Directions</b>                              | 2879 |

|                                                              |             |
|--------------------------------------------------------------|-------------|
| <b>64</b>                                                    |             |
| <i>Focused Ultrasound</i> . . . . .                          | <b>2883</b> |
| FERENC A. JOLESZ                                             |             |
| KULLERVO H. HYNYNEN                                          |             |
| Fundamental Principles of Focused Ultrasound Surgery         | 2883        |
| Interaction between Tissue and the Ultrasound Beam           | 2884        |
| Magnetic Resonance Imaging Guidance for Thermal Ablations    | 2884        |
| Magnetic Resonance Imaging–Guided Focused Ultrasound Therapy |             |
| Delivery Systems                                             | 2885        |
| Clinical Applications                                        | 2886        |
| Conclusion                                                   | 2889        |

|                                                                       |             |
|-----------------------------------------------------------------------|-------------|
| <b>65</b>                                                             |             |
| <i>Antisense Inhibition of Gene Expression</i> . . . . .              | <b>2891</b> |
| C. A. STEIN                                                           |             |
| LUBA BENIMETSKAYA                                                     |             |
| SRIDHAR MANI                                                          |             |
| Oligonucleotide Stability and Efficacy: The Role of Phosphorothioates | 2892        |
| Mechanism of Action of the Antisense Effect                           | 2894        |
| Delivery of Oligonucleotides into Cells                               | 2895        |
| Pharmacokinetics                                                      | 2896        |
| Clinical Studies                                                      | 2896        |
| Clinical Trials of G3139                                              | 2897        |

|                        |            |
|------------------------|------------|
| <i>Index</i> . . . . . | <b>I-1</b> |
|------------------------|------------|